

## *Curriculum Vitae*

**Reginald F. Frye**

March 2023

Office Address: University of Florida  
College of Pharmacy  
Department of Pharmacotherapy and Translational Research  
PO Box 100486, HPNP Room 3333  
Gainesville, FL 32610  
Phone: (352) 273-5453 | Fax: (352) 273-6242  
Email: frye@cop.ufl.edu

### **EDUCATION**

1995	University of Pittsburgh	PhD, Clinical Pharmaceutical Science
1990	Mercer University	PharmD, Doctor of Pharmacy
1986	Oglethorpe University	BS, Biology

### **POST-GRADUATE/OTHER TRAINING**

2021	UF SEC Certificate in Multicultural Mentoring
2014	UF Clinical and Translational Science Institute, Mentor Academy
2013	UF Clinical and Translational Science Institute, Academy of Research Excellence
2012-2013	Fellow, Academic Leadership Fellows Program, American Association of Colleges of Pharmacy
1991-1993	ASHP Fellow in Clinical Pharmacokinetics, Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh.
1990-1991	Clinical Pharmacokinetics Fellow and Clinical Instructor, School of Pharmacy, University of North Carolina at Chapel Hill. Preceptors: Drs. Gary R. Matzke and Stanley W. Carson.

### **PROFESSIONAL APPOINTMENTS AND POSITIONS**

2021-present	Associate Dean for Faculty Development, College of Pharmacy, University of Florida.
2012-present	Chair, Department of Pharmacotherapy and Translational Research
2012-present	Professor, Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida.
2003-2012	Associate Professor (with tenure), Departments of Pharmacotherapy and Translational Research (primary) and Pharmaceutics, College of Pharmacy, University of Florida (tenure awarded July 2004).
2003-2011	Graduate Coordinator, Department of Pharmacotherapy and Translational Research
2003-2008	Associate Director, Center for Pharmacogenomics, University of Florida
2002-2003	Associate Professor with tenure, Department of Pharmaceutical Sciences, School of Pharmacy, and Member, Center for Clinical Pharmacology, School of Medicine, University of Pittsburgh.
2001-2003	Associate Member, Center for Pharmacogenetics, School of Pharmacy, University of Pittsburgh.
1998-2003	Director, Clinical Pharmacology Analytical Facility, Center for Clinical Pharmacology, School of Medicine, University of Pittsburgh

1995-2002 Assistant Professor, Department of Pharmaceutical Sciences, School of Pharmacy, and Member, Center for Clinical Pharmacology, School of Medicine, University of Pittsburgh.  
1993-1996 Staff Pharmacist, Veterans Administration Medical Center, Pittsburgh, PA.

#### **PHARMACY LICENSURE**

1990 North Carolina, active

#### **HONORS AND AWARDS**

2017-2020 University of Florida Term Professorship  
2014 Keo Glidde Smith Fall Pharmacy keynote speaker, South Dakota State University College of Pharmacy  
2011 Teacher of the Year, University of Florida College of Pharmacy  
2011 Fellow, American College of Clinical Pharmacy  
2000 University of Pittsburgh Sr. Vice Chancellor's Research Seminar Series, Invited speaker  
1992 Gordon Research Conferences Graduate Student Travel Award  
1991-1993 American Society of Hospital Pharmacists Research and Education Foundation Fellowship in Clinical Pharmacokinetics 1991-1993  
1990 Hoechst-Roussel Excellence in Clinical Pharmacy Award  
1990 Summa Cum Laude graduate, Mercer University  
1989 Mercer University Dean's Merit Scholarship  
1989 Phi Kappa Phi National Honor Society  
1988 Rho Chi Honor Society  
1987 M.A. Chambers Award for Academic Achievement  
1986-1990 Mercer University Dean's List

#### **MEMBERSHIPS IN PROFESSIONAL AND SCIENTIFIC SOCIETIES**

American Association of Colleges of Pharmacy, 1995 – present  
American Association of Pharmaceutical Scientists, 1991 – 2016  
American College of Clinical Pharmacy, 1990 – present  
American College of Clinical Pharmacology, 2003-2008  
American Society for Clinical Pharmacology and Therapeutics, 1997 – present  
American Society of Health-System Pharmacists, 1986-1997  
International Society for the Study of Xenobiotics, 1992 – present

#### **TEACHING RESPONSIBILITIES**

**UNIVERSITY OF FLORIDA, 2003 – present**

**Appointed to Graduate Faculty: Pharmaceutics November 2003; Pharmacotherapy and Translational Research 2009, Clinical Investigation 2011.**

##### **College of Pharmacy:**

###### *Professional*

PHA5930	2020 –	Seminars in Pharmacy Research (15 contact hours)
PHA5132	2016 – 2019	Principles of Drug Therapy Individualization (8 contact hours)
PHA5113	2004 – 2016	Personalized Medicine (Course coordinator, 12-16 contact hours)
PHA3931	2011 – 2015	Honors Seminar: In Search of Magic Bullets (1 contact hour)
PHA5782	2003 – 2012	Pharmacotherapy II (drug dosing in renal disease, clinical pharmacokinetics of cardiovascular drugs, and drug interactions; 6 contact hours)

PHA5121	2004 – 2008	Advanced Clinical Pharmacokinetics (2-4 lecture hours)
PHA5783	2004 – 2008	Pharmacotherapy III (clinical pharmacokinetics of anti-epileptic and anti-infective drugs; 5 lecture hours)

*Graduate*

PHA6427	2005 – 2016	Pharmacogenetics of Drug Metabolism and Transport (Course developer and coordinator; 20-24 contact hours; offered even years)
PHA6449	2012 – 2016	Pharmacogenomics (2 contact hours; offered even years).
PHA6633	2012 – 2014	MTM: A Cardiovascular Focus (2 lecture hours)
PHA6635	2012 – 2014	MTM: A Renal Focus (3 lecture hours)
PHA6935	2020 – present	Foundations in Clinical Pharmacology (Course Coordinator, 10 lecture hours)

College of Medicine:

Drug Metabolism and Transport in CKD and ESRD. Renal Conference (given annually for new nephrology fellows), Division of Nephrology, Hypertension & Renal Transplantation, Department of Medicine, 2010 – 2015.

**UNIVERSITY OF PITTSBURGH, 1993 – 2003**School of Pharmacy:*Professional*

Pharm 3407	1993 - 1998	Clinical Pharmacokinetics (Lecturer in Population & Bayesian Pharmacokinetics, Computer applications, Theophylline, Phenytoin; 20 contact hours)
Pharm 3402	1997	Pharmacokinetic Concepts (Course Coordinator, 10 contact hours)
Pharm 3002	1995 – 2003	Advanced Pharmacokinetics (Lecturer; 14-22 contact hours)
Pharm 1790	1995 – 2003	Undergraduate Research
Pharm 5218	1998 – 2003	Drug Development 2 (PK/Drug Metabolism Course for PharmD students; Course Coordinator 1998-2001; 18-24 contact hours)

*Graduate*

Pharm 3102	1995 – 2001	Drug metabolism (Course Coordinator; 6 contact hours)
Pharm 3027	1997 – 2003	Topics in Biopharmaceutics/Pharmacokinetics
Pharm 3020	2002 – 2003	Pharmacogenomics (Course Coordinator; 17 contact hours)
Pharm 3021	2002 – 2003	Topics in Pharmacogenomics (Course Coordinator; 14 contact hours)

School of Medicine (1996 to 1998, 2001)

Med 5710	1996 – 1998	Selective Course in Clinical Pharmacology (Lecturer in Pharmacokinetic Concepts for Clinicians, Drug removal during continuous dialytic procedures; 5 contact hours)
Med 5710	2001	Selective Course in Clinical Pharmacology (Facilitator in Pharmacokinetic Concepts for Clinicians; 3 contact hours)

**UNIVERSITY OF NORTH CAROLINA, 1991:**

<i>Pharm.D. Curriculum</i>	PhPr 139	Computer Applications in Clinical Pharmacokinetics (4 contact hours)
<i>Undergraduate</i>	PhPr 77	Pharmacotherapeutics (4 contact hours)

**EDUCATIONAL RESEARCH***University of Florida*

Professional Pharmacy Students: 2004: Melonie Potvin, Fiadora Avramidis, Julio Duarte. 2005: Erika Diaz, Tanisha Cooper, Matthew Soto, Dana Fishbain, 2006: Jason Karnes, Tyler Barker. 2007: Stephen Harvey, Jessica Enogieru. 2009:

Tiffany Tseng. 2010: Shirley Elisbrun, Charles Fletcher, Jenna Rhoades. 2011: Chestine Libema, Danielle Honein. 2012: Mark Lahey. 2013: Michael Sherwood. 2014: Stanley Luc. 2015, 2016: Thakul Rattanasuwan. 2017: Nicholas Tran.

Undergraduate Students (\*=University Scholars Program): 2011: Brendan Kelly. 2013-14: Julius Lukas\*.

### ***University of Pittsburgh***

Undergraduate Students: 1999-2000, Ivan Colaizzi.

Graduate Students: 2000: Aarti Ranade, Mohammed Al-Dosary. 2001: Matthew Hruska. 2002: Gregor Bendor.

Professional Pharmacy Students: 1996: Robert Berringer. 1998: Jodie Campbell. 1998: Susan Byrne. 1999: Madelaine Betancourt. 1999: Thomas Nolin, MS, Matthew Hruska. 2000: Bill Gentsch. 2001: Shelby Corman, Sara Bristol. 2002: Steven Ganchuk, Irina Sheyko.

UPMC Hospital Pharmacy Residents: Patricia Pecora, PharmD, 1995-6, Lisa (Dreger) Opatik, PharmD, 1996-7, Brian Kearney, PharmD, 1997, Michael Shullo, PharmD, 1997-8, Laurel Riemenn, PharmD, 1998-9, Jackie Dix, PharmD, 2002.

## **GRADUATE RESEARCH**

### ***University of Florida***

Member, Graduate Faculty: Pharmaceutical Sciences 2003, Clinical Investigation 2011.

#### Graduate Major Advisor

##### *Clinical Pharmaceutical Scientist Program*

Prajakta Dravid	M.S. degree	December 2007
Mohamed Eslam Mohamed	Ph.D. degree	May 2010
Melonie (Potvin) Stanton	Ph.D. degree	April 2012
Marina Kawaguchi-Suzuki	Ph.D. degree	August 2015
Ahmed Albassam	Ph.D. degree	August 2015
Ahmed Alalaiwe	Ph.D. degree	August 2015
Wen-yi (Archie) Li (co-advisor)	M.S. degree	December 2018
Shaimaa Elbalkiny	M.S. degree	May 2021

#### Graduate Committee Member

##### *Clinical Pharmaceutical Scientist Program*

Hrishikesh Navare	M.S. degree	May 2009
Elvin D. Price, Pharm.D.	Ph.D. degree	December 2009
MyPhoung Le	Ph.D. degree	April 2010
Daniel Gonzalez, Pharm.D.	Ph.D. degree	July 2012
Eric Egelund, Pharm.D.	Ph.D. degree	August 2014
Abdullah Sultan, Pharm.D.	Ph.D. degree	December 2015
Wael Alghamdi, Pharm.D.	Ph.D. degree	May 2019
Bradley Stockard, Pharm.D.	Ph.D. degree	May 2019
Abdelrahman Elsayed	Ph.D. degree	May 2021
Yuli Qian	Ph.D. degree	May 2021
Richard J. Marrero	Anticipated Graduation:	2023
Nam Nguyen	Anticipated Graduation:	2023

##### *Department of Pharmaceutics*

Immo Zdrojewski	Ph.D. degree	May 2008
Li Li	Ph.D. degree:	April 2013

#### Post-Doctoral Fellows

Mohamed Eslam Mohamed, Ph.D.	May 2010 – August 2013
------------------------------	------------------------

### ***University of Pittsburgh***

Member, Graduate Faculty 1997.

#### **Graduate Major Advisor**

##### *Clinical Pharmaceutical Scientist Program*

J. Ike Lee, Pharm.D.	Ph.D. degree	April 2001
Khalid Alkharfy, Pharm.D.	Ph.D. degree	July 2002
Thomas Nolin, M.S., Pharm.D.	Ph.D. degree	May 2003
Matthew Hruska, Pharm.D.	Ph.D. degree	October 2004
Rama Sivasubramanian, M.S.	Ph.D. degree	November 2005
Sara Fitzgerald (Genetic Counseling)	M.S. degree	April 2004

#### **Graduate Committee Member**

##### *Clinical Pharmaceutical Scientist Program*

Amy Pittenger, Pharm.D.	M.S. degree	August 1996
Thomas Dowling, Pharm.D.	Ph.D. degree	June 1999
Firoozeh S. Salek, Pharm.D.	Ph.D. degree	July 1999
Maggie Folan, RN, BSN	Ph.D. degree	July 2003

##### *Department of Pharmaceutical Sciences*

Fahd Al-Genoby, B.S.	Ph.D. degree	December 2000
Vinod Ramachandran, M.S.	Ph.D. degree	January 2001
Jaya Pisaputi, M.S.	Ph.D. degree	August 2001
Elsa Crick (GSPH)	M.S. degree	April 2002
Vera Donnenberg, MS	Ph.D. degree	July 2002
Abdullah Al-Mohizea	Ph.D. degree:	November 2002
Matthew Hummel (WVU)	M.S. degree:	January 2003
Junhai Oo	M.S. degree:	February 2003
Christopher Bolcato	M.S. degree:	June 2003
Bernard Komoroski	Ph.D. degree	March 2005
William Zamboni	Ph.D. degree	May 2005
Aarati Ranade	Ph.D. degree	November 2005

#### **Comprehensive Examination Committee Member (Department of Pharmaceutical Sciences)**

Mohammed Al-Dosary	January 2003
Gregor Bender	March 2003

### **UNIVERSITY SERVICE**

#### **University of Florida**

##### *University*

Academic Freedom, Tenure, Professional Relations, and Standards Committee (AFTPRS), Faculty Senate standing committee, 2017 – 2020

Faculty Enhancement Opportunely Awards Review Committee, 2021

Quality Assurance Committee, UF Online, 2013 – 2017

University Constitution and Regulations Committee, Faculty Senate standing committee, 2018 – 2021

University Libraries Committee (Faculty Senate standing committee), 2009 – 2011

##### *Health Science Center*

Health Science Center Task Force on Team Science Recognition for Promotion and Tenure, 2015 – 2016

Health Science Center White Paper committees, (1) research training grants, and (2) interprofessional education, 2014

Preeminence Initiative: Genomic medicine search committee, 2014 – 2015

Preeminence Initiative: Metabolomics Coordinating Committee (search committee), 2013 – 2015  
Personalized Medicine Program Subcommittee, UF Health P&T Committee, 2012 – 2014  
Search committee member, Dean, College of Nursing, October 2012 – April 2013  
CTSI Clinical Research Center Scientific Advisory Committee, 2005 – 2018  
CTSI Scientific Reviewer (ad hoc), 2018 – present  
Advanced Post Graduate Program in Clinical Investigation, Advisory Committee, 2007 – 2015  
CTSA Training Core Committee, 2006 – 2007

#### *College of Pharmacy*

Academic and Professional Standards Committee, 2011 – 2016  
ACPE 2020 Self-Study –  
ACPE Organization & Administration Self-Study Committee, Chair, 2020  
Steering Committee, Member, 2020  
Dean for Clinical Affairs Search Committee, Chair, 2013  
COP Academic Standards Task Force, 2016  
COP Orientation Task Force, 2015, 2016  
Curriculum Revision Task Force, Chair, 2013-2014  
Department of Pharmaceutics Chair and Center for Pharmacometrics and Systems Pharmacology Director,  
Faculty Search Committee, Chair, 2017 – 2018  
Department of Pharmacy Practice/Pharmacotherapy and Translational Research, Faculty search  
committee: 2004 (two committees), 2005 (chair), 2007 (chair), 2008 (two committees).  
Director for Continuing Pharmacy Education, Search Committee, Chair, 2016  
Equipment committee, 2003 – 2008  
Executive Committee, 2012 – 2013, 2021 – present  
Faculty Awards, 2016 – 2021, Chair 2018 – 2021  
Graduate Coordinator, Department of Pharmacotherapy and Translational Research, 2004 – 2011  
Graduate Studies Committee, 2005 – 2011  
Preeminence Initiative: Drug Discovery and Development Faculty Search Committee, Chair, 2013 – 2016  
Research Committee, 2012 – 2018  
Rho Chi, faculty advisor, 2007 – 2018  
Tenure and Promotion Committee, 2004 – 2006, 2006 – 2008

#### **University of Pittsburgh**

##### *University*

Department of Anesthesiology and Critical Care Medicine, Manuscript Review Committee, 1996  
Departmental and Faculty Computing Working Group of the Executive Committee for Academic  
Computing, University of Pittsburgh, 1996 – 1999.  
GCRC Education Committee, 2001 – 2003  
General Clinical Research Center Advisory Committee, 1999 – 2003.  
University of Pittsburgh Cancer Institute, Clinical Pharmacology Core Advisory Committee, 2002 - 2003  
University of Pittsburgh, Biomedical Institutional Review Board, 1998 – 2003.

##### *School of Pharmacy*

Code of Conduct Committee, School of Pharmacy, 1996 – 2000.  
Department of Pharmaceutical Sciences Faculty Search Committee: Neuropsychiatry position 1998,  
Population pharmacokinetics position 2000.  
Department of Pharmaceutical Sciences, Graduate Program Council, 2002 – 2003.  
Department of Pharmaceutical Sciences, Research Seminar Committee, 1997 – 2003.  
Department of Pharmacy and Therapeutics Faculty Search Committee: Cardiology 1997, MICU 1997,  
Internal medicine 1998-9, Internal Medicine 2000, Infectious Disease 2001-2.

Graduate Committee, School of Pharmacy, 1998 – 2001.

Interferon treatment and drug interactions – KQV radio interview

University of Pittsburgh Pharmacy Associates, Advisory Committee, 1998 – 2000.

## **PROFESSIONAL SERVICE**

### **National Institutes of Health**

#### *Study Section/Grant Review*

Center for Scientific Review: Special Emphasis Panel (SEP) member (ZRG1 RPHB-B (05): Cancer Treatment), Ad hoc reviewer, November 2004. SEP member (ZRG1 RPHB-B (05) and ZRG1 RPHB-J (02)), Ad hoc reviewer, July 2005. SEP member (ZRG1 EMNR V55 R), PAR-15-024: Molecular Profiles and Biomarkers of Food and Nutrient Intake, November 2015. SEP member and Co-Chair (ZRG1 EMNR-V 55 R), November 2016. SEP member (ZRG1 EMNR V55 R), March 2018. Reviewer (ENMR IRG), NIH CSR SSI Anonymization Project, January 2019.

Center for Scientific Review: Risk, Prevention and Intervention for Addictions (RPIA) Study Section, Temporary member, June 2010, September 2010, February 2011, June 2011, September 2011, February 2012.

National Center for Complementary and Alternative Medicine: Special Emphasis Panel member (ZAT1 CP10), Cranberry: Urinary Tract Infection and Other Conditions, September 2003.

National Center for Complementary and Alternative Medicine, with the Office of Dietary Supplements (ODS) and the National Cancer Institute (NCI / NIH): SEP member, RFA-At-11-001 Mechanistic Research on CAM Natural Products (R01): (ZAT1 SM24) July 2011; (ZAT1 SM25) March 2012; (ZAT1 SM29) September 2013.

National Center for Complementary and Integrative Health (formerly NCCAM): SEP member (ZAT1 HS19), Center of Excellence for Research on CAM (P01), March 2015. SEP member (ZAT1 SM37), Training and Education in Natural Products, July 2015. SEP member (ZAT1 SM38), Clinical Research on Natural Products (R21 and R33), November 2015. SEP member/Co-Chair (ZAT1 SM42), Training and Education in Natural Products, July 2016. SEP member and Co-Chair, (ZAT1 YW01), Exploratory Clinical Trials and Studies of Natural Products in NCCIH High Priority Research Topics (R61/R33 & R33), March 2017. SEP member (ZAT1 AJTo3 1), Training and Education in Natural Products, July 2017. SEP member (ZAT1 VS09), Fellowship, Career Development and Research Grant Programs, April 2018. SEP member (ZAT1 AJTo7), LRP review panel, April 2018. SEP Member and Chair (ZAT1 AJTo8), Discovery and Biological Signatures of Diet-Derived Microbial Metabolites (R01), July 2018. SEP member (ZAT1 VS12), Training and Research grants, November 2018. SEP member (ZAT1 SM47), Institutional Research Training Grants, May 2019. SEP member (ZAT1 SM50), Early Phase Clinical Trials of Natural Products (R33 and R61/R33) and Natural Products Phase II Clinical Trial Cooperative Agreements (U01), July 2019. SEP member (ZAT1 SM52), Institutional Research Training Grants (IT) (T90/R90), November 2019. SEP member (ZAT1 SM54), Early Phase Clinical Trials of Natural Products (R33 and R61/R33), April 2020. Chair, (ZAT1 SM59), Institutional Research Training Grants (IT) (T32), October 2020. SEP member (ZAT1 PS01), Pilot Projects Increasing the Impact of the NIH Centers for Advancing Research on Botanicals and Other Natural Products (CT) (R03), February 2021. SEP member (ZAT1 PS02), NCCIH Training and Education Review Panel, February 2021. SEP Member (ZAT1 SH01), NCCIH Early Phase Clinical Trials of Natural Products. July 2021. SEP member (ZAT1 PS05), NCCIH Training and Education Review Panel, November 2021. Chair, (ZAT1 SH04), Early Phase Clinical Trials of Natural Products (NP), January 2022. SEP Member, (ZAT1 JM10), NCCIH Training and Education Review Panel. Chair, SEP (ZAT1 MH01), Early Phase Clinical Trials of Natural Products, September 2022. SEP Member (ZAT1 JM13), NCCIH Training and Education Review Panel, November 2022. SEP Member, (ZAT1 MH03), Loan repayment program.

National Institute of General Medical Sciences: SEP member (ZGM1 PPBC-7 (VD)), Review of Program Project (Po1) Applications, August 2011.

National Institute of Mental Health: SEP member (ZMH1-CRB-B-01), Research on the Mental Health of Minority Populations, December 2001.

National Institute of Neurological Disorders and Stroke: SEP member (ZNS1 SRB-G (48)), Translational Stroke, July 2010. SEP (ZNS1 SRB-G (49)), April 2011. SEP (ZNS1 SRB-G (60)), November 2012.

NIH (NCCAM) and the Office of Dietary Supplements (ODS/NIH): Stage 2 Reviewer, Botanical Dietary Supplement Research Centers and Centers for Advancing Natural Products Innovation and Technology Centers (CANPIT) (U41), (ZAT1SM35), December 2014.

#### *NIH/Other Committees*

National Human Genome Research Institute, Editorial Board Member (Pharmacist), the Genetics/Genomics Competency Center (G2C2) <http://www.g-2-c-2.com>. Sept 2012 to August 2015.

National Center for Complementary and Alternative Medicine, Dietary Supplement Drug Interaction Expert Advisory Committee, 2012-2014.

#### **American Association of Colleges of Pharmacy (AACP)**

AACP 2020 INterim Meeting Planning Committee, 2019

AACP 2020 Research Symposium Planning Committee, 2019

AACP 2020 Volwiler Research Achievement Award Committee, 2019

Council of Faculties, Department Chairs Learning Community (COF committee), 2017-2020, Chair 2019-20.

Rufus A. Lyman Award selection committee, 2014-15, 2015-16

Pharmacy Practice Section Scholarship and Research Committee, 2016-2017

Pharmacy Practice Section Award Committee, 2021 – present

PPS Research Achievement Award Subcommittee, 2021-2022

#### **American Association of Pharmaceutical Scientists (AAPS)**

Abstract Reviewer, Annual Meeting, 1996, 1997

Abstract Screening Committee, Clinical Science Section Chair, 1997

Clinical Science Research Achievement Award Selection Committee, 1997

Hot Topics Committee, 2004 Annual Meeting

#### **American College of Clinical Pharmacy (ACCP)**

Abstract Reviewer, Annual and/or Spring Meetings, multiple years since 1997

ACCP Research Institute, Pharmacotherapy Review panel, 1998, 2002.

Founding Faculty member, Focused Investigator Training (F.I.T.) Program, July 2008

Faculty Mentor, Focused Investigator Training (F.I.T.) Program, 2009, 2010, 2011, 2013, 2014

#### **American Society for Clinical Pharmacology and Therapeutics (ASCPT)**

Abstract Reviewer, Annual Meeting, pharmacokinetics/drug metabolism section 1999 – 2009, 2012

Membership Committee, 2001 – 2004

Vice-Chair, Pharmacokinetics and drug metabolism section, 2006 – 2010

Steering Committee Member, Pharmacometrics and Pharmacokinetics (PMK) section, 2010 – 2012

#### **International Society for the Study of Xenobiotics (ISSX)**

Scientific Advisory Board, 2010

2011 Annual Meeting: Meeting Organizing Committee

2015 Annual Meeting: Meeting Organizing Committee, Abstract Review Committee, Poster Awards Review Committee



### Other

PPP Foundation, London, England. Grant review panel member, Themed Grant: Older People Program. January 2002.

### Editorial Board Member

Pharmacotherapy, 2006 – 2016  
Annals of Pharmacotherapy, 2008 –  
Frontiers in Pharmacogenetics and  
Pharmacogenomics, 2012 –

The Open Drug Metabolism Journal, 2007 – 2014  
ISRN Pharmacology, 2010 – 2013

### Manuscript Reviewer

#### Regular

Annals of Pharmacotherapy  
Clinical Pharmacology and Therapeutics  
Frontiers in Pharmacogenetics and  
Pharmacogenomics

Journal of Clinical Pharmacology  
Journal of Pharmacology and Experimental  
Therapeutics  
Pharmacotherapy

#### Intermittent

American Journal of Health-Systems Pharmacy  
American Journal of Kidney Disease  
American Journal of Obstetrics and Gynecology  
American Journal of Pharmaceutical Education  
American Journal of Transplantation  
Biological Psychiatry  
Biomedical Chromatography  
British Journal of Clinical Pharmacology  
Cancer Chemotherapy and Pharmacology  
Chromatographia  
Clinical Pharmacokinetics  
Digestive Diseases and Sciences  
Drug Metabolism and Disposition  
European Journal of Clinical Pharmacology  
Food and Chemical Toxicology  
Gerontology  
Human Genetics

Journal of Antimicrobial Chemotherapy  
Journal of Pharmaceutical and Biomedical Analysis  
Journal of Chromatography A  
Journal of Chromatography B  
Journal of Clinical Psychopharmacology  
Journal of Pharmacology and Experimental  
Therapeutics  
Journal of Pharmacy Technology  
Kidney International  
Life Sciences  
Open Drug Metabolism Journal  
Pediatrics  
Pharmaceutical Research  
Pharmacogenetics and genomics  
Planta Medica  
The Open Drug Metabolism Journal

### Consulting Activities

Abbott Laboratories, Pharmacokinetics/drug metabolism consultant, 1996-8  
Baxter Pharmaceutical Products, (formerly Ohmeda, Inc.), Pharmacokinetics consultant, 1993- 2001  
Bayer Corporation, drug metabolism/drug interaction consultant, 2004  
Otsuka America Pharmaceutical, Inc., Pharmacokinetics/drug metabolism/Analytical consultant, 1995-9.  
PharmaSolutions, consultant, drug-drug interactions, 2004

### PUBLICATIONS

#### BOOK CHAPTERS:

1. Matzke GR, Luke DR, **Frye RF**, Dupuis RE. Dialysis and Renal Transplantation. In: Herfindal ET, Gourley DR, Hart LL (eds.). Clinical Pharmacy and Therapeutics. Fifth Edition. Baltimore, MD: William and Wilkins, 1992:372-392.

2. Matzke GR, **Frye RF**. Drug dosing in renal failure. In: Posey LM, DiPiro J, Talbert R, Hayes P, Yee G, Matzke GR (eds.). *Pharmacotherapy: A Pathophysiologic Approach*. Second Edition. Amsterdam: Elsevier Science Publishers B.V., 1992:750-763.
3. **Frye RF**, Matzke GR. Vancomycin. In: Murphy JE (ed.). *Clinical Pharmacokinetics Pocket Reference*. American Society of Hospital Pharmacists' Special Projects Division, 1993:281-291.
4. Matzke GR, **Frye RF**: Drug therapy individualization for patients with renal insufficiency. In: *Pharmacotherapy: A Pathophysiologic Approach*, Third Edition. DiPiro J, Talbert R, Yee G, Matzke GR, Wells B, Posey LM, (eds). Appleton & Lange: Norwalk, CT, 1996.
5. **Frye RF**, Matzke GR: Drug therapy individualization for patients with renal insufficiency. In: *Pharmacotherapy: A Pathophysiologic Approach*, Fourth Edition. DiPiro J, Talbert R, Yee G, Matzke GR, Wells B, Posey LM, (eds). Appleton & Lange: Norwalk, CT, 1999.
6. **Frye RF**, Matzke GR. Vancomycin. In: Murphy JE (ed.). *Clinical Pharmacokinetics Pocket Reference*. Second edition. American Society of Health-System Pharmacists' Special Publishing, 2001:375-87.
7. **Frye RF**, Matzke GR: Drug therapy individualization for patients with renal insufficiency. In: *Pharmacotherapy: A Pathophysiologic Approach*, Fifth Edition. DiPiro J, Talbert R, Yee G, Matzke GR, Wells B, Posey LM, (eds). Appleton & Lange: Norwalk, CT, 2002.
8. **Frye RF**, Capitano B, Matzke GR. Vancomycin. In: Murphy JE (ed.). *Clinical Pharmacokinetics Pocket Reference*. Third edition. American Society of Health-System Pharmacists' Special Publishing, 2005; pages 349-64.
9. **Frye RF**. Pharmacogenetics of oxidative drug metabolism and its clinical application. *Pharmacogenomics: Applications to Patient Care*. American College of Clinical Pharmacy, Kansas City, MO. 2004; 273-307.
10. \*Nolin TD, **Frye RF**. Potential Role of Pharmacogenetics in Improving Medication Adherence. In: *Methodological Issues in the Study of Adherence*. Dunbar-Jacob J, Erlen J, Schlenk E, and Stilley C, (eds). University of Pittsburgh Press, Pittsburgh, PA, 2005; pages 121-33.
11. **Frye RF**, Matzke GR: Drug therapy individualization for patients with renal insufficiency. In: *Pharmacotherapy: A Pathophysiologic Approach*, Sixth Edition. DiPiro J, Talbert R, Yee G, Matzke GR, Wells B, Posey LM, (eds). McGraw-Hill Companies: New York, NY; pages 919-35.
12. Capitano B, **Frye RF**, Matzke GR. Vancomycin. In: Murphy JE (ed.). *Clinical Pharmacokinetics Pocket Reference*. Fourth edition. American Society of Health-System Pharmacists' Special Publishing, 2007; Chapter 20, pages 329-44.
13. Matzke GR, **Frye RF**: Drug therapy individualization for patients with renal insufficiency. In: *Pharmacotherapy: A Pathophysiologic Approach*, Seventh Edition. DiPiro J, Talbert R, Yee G, Matzke GR, Wells B, Posey LM, (eds). McGraw-Hill Companies: New York, NY, 2008; pages 833-44.
14. **Frye RF**. Pharmacogenetics of oxidative drug metabolism and its clinical application. *Pharmacogenomics: Applications to Patient Care*. Second Edition. American College of Clinical Pharmacy, Lenexa, KS. 2009; pages 32-53.
15. \*Kawaguchi-Suzuki M, Nelson DR, **Frye RF**. Pharmacogenetics of Hepatitis C Treatment. *Pharmacogenomics: Applications to Patient Care*. Third Edition. American College of Clinical Pharmacy, Lenexa, KS. 2015; Chapter 14, pages 216-232.
16. Frye RF. Pharmacogenomics. *Winter's Basic Clinical Pharmacokinetics*, Sixth Edition. Wolters Kluwer Health, Philadelphia, PA. 2018; Chapter 5; pages 154-160.
17. Mosley S, Frye RF. Pharmacogenomics. *Beringer's and Winter's Basic Clinical Pharmacokinetics*, Seventh Edition. Wolters Kluwer Health, Philadelphia, PA. Submitted.

### LETTERS, CASE REPORTS, MISCELLANEOUS:

1. Marshall LL, Frye RF, Murphy JE. Students' experience in a phase III clinical trial. *Am J Hosp Pharm* 1990; 47:1014-6.
2. Frye RF, Matzke GR. Book review: Infectious Diseases: Prophylaxis & Chemotherapy. *Am J Hosp Pharm* 1991; 48:843-7.
3. Frye RF, Job ML, Dretler RH, Rosenbaum BJ. Teicoplanin nephrotoxicity: First case report. *Pharmacotherapy* 1992;12(3):240-242.
4. Gleason PP, Frye RF, O'Toole T. Debilitating reaction following the initial dose of tramadol. *Ann Pharmacother* 1997;31:1150-2.
5. \*Kawaguchi-Suzuki M, Frye RF. Pharmacogenomics and therapy for hepatitis C virus infection. *Clinical Laboratory International* 2014 November: 18-20. Non-peer-reviewed.

### PEER-REVIEWED ARTICLES – REVIEW PAPERS:

\* = individuals in training

1. Matzke GR, **Frye RF**. Drug administration in patients with renal insufficiency: Minimizing renal and extrarenal toxicity. *Drug Safety* 1997;16(3):205-231.
2. Kroboth PD, \*Salek FS, \*Pittenger AL, \*Fabian TJ, **Frye RF**. DHEA and DHEA-S: A Review. *J Clin Pharmacol* 1999; 39(4):327-48.
3. \*Nolin TD, **Frye RF**, Matzke GR. Hepatic Drug Metabolism and Transport in Patients with Kidney Disease. *Amer J Kid Dis* 2003; 42(5):906-925.
4. **Frye RF**. Probing the World of Cytochrome P450 Enzymes. *Mol Interv*. 2004 Jun;4(3):157-62.
5. \*Mohamed MF, **Frye RF**. Effects of herbal supplements on drug glucuronidation. Review of clinical, animal, and in vitro studies. *Planta Med*. 2011 Mar;77(4):311-21. PMID: 21049395.
6. \*Kawaguchi-Suzuki M, **Frye RF**. Current clinical evidence on pioglitazone pharmacogenomics. *Front Pharmacol* 2013;4:147. doi: 10.3389/fphar.2013.00147. PMID: 24324437. PMCID: PMC3840328.
7. \*Kawaguchi-Suzuki M, **Frye RF**. The Role of Pharmacogenetics in the Treatment of Chronic Hepatitis C Infection. *Pharmacother* 2014;34(2):185-201. doi: 10.1002/phar.1349. PMID: 24114761.
8. An G, \*Mukker JM, Derendorf H, **Frye RF**. Enzyme- and Transporter-Mediated Beverage-Drug Interactions: an Update on Fruit Juices and Green Tea. *J Clin Pharmacol* 2015; 55(12): 1313-31. doi: 10.1002/jcph.563. PMID: 26095990.

### PEER-REVIEWED ARTICLES – ORIGINAL RESEARCH:

\* = Trainees working under my direction are indicated by an asterisk

1. Stiff DD, **Frye RF**, Branch RA. Sensitive high-performance liquid chromatographic determination of chlorzoxazone and 6-hydroxychlorzoxazone in plasma. *J Chromatogr B* 1993;613:127-131.
2. Kisor DF, **Frye RF**, Kudsk KA. Estimation of the hepatic extraction ratio of indocyanine green in swine. *Clin Sci* 1993;84:681-685.
3. Carcillo J, Romkes-Sparks M, Parise RA, Adedoyin A, **Frye RF**, Branch RA. CYP2D6 mRNA expression in circulating peripheral blood mononuclear cells correlates with *in vivo* debrisoquine hydroxylase activity in extensive metabolizers. *Res Comm Molec Pathol Pharmacol* 1996;91(2):149-159.
4. Matzke GR, **Frye RF**, \*Alexander A, Reynolds R, Dixon R, Johnston J, Rault R. The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefene. *J Clin Pharmacol* 1996;36:144-151.
5. **Frye RF**, Branch RA. Improved high performance liquid chromatographic determination of debrisoquine and 4-hydroxydebrisoquine in human urine following direct injection. *J Chromatogr B* 1996;677:178-82.

6. Karara AH, **Frye RF**, Hayes PE, Weaver ML, Rault R, Robinson WT, Matzke GR. Pharmacokinetics of abecarnil in patients with renal insufficiency. *Clin Pharmacol Ther* 1996;59:520-8.
7. **Frye RF**, Matzke GR, Jallad NS, Wilhelm JA, Bikhazi GB. The effect of age on the pharmacokinetics of the opioid antagonist nalmefene. *Br J Clin Pharmacol* 1996;42:301-306.
8. **Frye RF**, Stiff DD. Determination of chlorzoxazone and 6-hydroxychlorzoxazone in human plasma and urine by high performance liquid chromatography. *J Chromatogr B* 1996;686: 291-6.
9. **Frye RF**, Matzke GR, Dixon R, Schade RR, Rabinovitz M. Effects of liver disease on the disposition of the opioid antagonist nalmefene. *Clin Pharmacol Ther* 1996;61(1):15-23.
10. **Frye RF**, Matzke GR, Adedoyin A, Porter J, Branch RA. Validation of the Pittsburgh cocktail approach to assess selective regulation of drug metabolizing enzymes. *Clin Pharmacol Ther* 1997;62(4):365-376.
11. **Frye RF**, Adedoyin A, Mauro K, Matzke GR, Branch RA. Use of chlorzoxazone as an in vivo probe of Cytochrome P<sub>450</sub> 2E1: Choice of dose and phenotypic trait measure. *J Clin Pharmacol* 1998;38:82-89.
12. Burckart GJ, **Frye RF**, \*Kelly P, Branch RA, Jain A, Fung JJ, Starzl TE, Venkataramanan R. Induction of CYP2E1 activity in liver transplant patients as measured by chlorzoxazone 6-hydroxylation. *Clin Pharmacol Ther* 1998;63:296-302.
13. **Frye RF**, Stiff DD, Branch RA. A sensitive method for the simultaneous determination of caffeine and its dimethylxanthine metabolites in human plasma: Application to CYP1A2 phenotyping. *J Liq Chrom Rel Tech* 1998;21(8):1161-71.
14. \*Joy MS, Matzke GR, **Frye RF**, Palevsky PM. Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. *Am J Kidney Dis* 1998; 31:1019-1027.
15. Marx MA, **Frye RF**, Matzke GR, Golper TA. Cefazolin as empiric therapy in hemodialysis-related infections: Efficacy and blood concentrations. *Am J Kidney Dis* 1998;32:410-414.
16. Adedoyin A, **Frye RF**, Mauro K, Branch RA. Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail. *Br J Clin Pharmacol* 1998;46(3):215-9.
17. \*Dowling TC, **Frye RF**, Zemaitis MA. Simultaneous determination of para-aminohippuric acid, acetyl-para-aminohippuric acid and iothalamate in human plasma and urine by high-performance liquid chromatography. *J Chromatogr B* 1998; 716:305-13.
18. Murphy JE, Austin ML, **Frye RF**. Evaluation of gentamicin pharmacokinetics and dosing protocols in 195 neonates. *Amer J Health Syst Pharm* 1998; 55(21):2280-8.
19. Grabe DW, Bailie GR, Eisele G, **Frye RF**. Pharmacokinetics of intermittent intraperitoneal ceftazidime. *Am J Kidney Dis* 1999; 33(1):111-7.
20. Manley HJ, Bailie GR, Asher RD, Eisele G, **Frye RF**. Pharmacokinetics of intermittent intra-peritoneal cefazolin in continuous ambulatory peritoneal dialysis patients. *Perit Dial Int* 1999;19:65-70.
21. \*Dowling TC, **Frye RF**, Fraley DS, Matzke GR. Comparison of iothalamate clearance methods for measuring GFR. *Pharmacotherapy* 1999;19(8):943-50.
22. \*Dowling TC, **Frye RF**. Determination of famotidine in human plasma and urine by high-performance liquid chromatography. *J Chromatogr B Biomed Sci Appl* 1999;732:239-43.
23. **Frye RF**, Tammara B, Cowart TD, Bramer SL. Effect of disulfiram-mediated CYP2E1 inhibition on the disposition of vesnarinone. *J Clin Pharmacol* 1999; 39(11):1177-1183.
24. Matzke GR, **Frye RF**, Early JJ, Straka RJ, Carson SW. The influence of diabetes on drug metabolism. *Pharmacotherapy* 2000; 20(2):182-90.
25. Matzke GR, **Frye RF**, \*Joy MS, Palevsky PM. Determinants of ceftazidime clearance by CVVH and CVVHD. *Antimicrob Agent Chemother* 2000 Jun;44(6):1639-44.

26. **Frye RF**, Kroboth FJ, Stone RA, Folan MM, Salek FS, Pollock BG, Linares AM, Hakala C, Kroboth PD. Sex differences in the pharmacokinetics of dehydroepiandrosterone (dhea) following single and multiple-dose administration in healthy older adults. *J Clin Pharmacol* 2000; 40:596-605.
27. Matzke GR, **Frye RF**, \*Joy MS, Palevsky PM. Determinants of ceftriaxone clearance by CVVH and CVVHD. *Pharmacotherapy* 2000; 20(6):635-43.
28. Manley HJ, Bailie GR, **Frye RF**, Hess LD, McGoldrick MD. Pharmacokinetics of intermittent intravenous cefazolin and tobramycin in patients treated with automated peritoneal dialysis. *J Am Soc Neph* 2000; 11: 1310-16.
29. Rosen DA, Morris JL, Rosen KR, Steelman RJ, Gustafson RA, Wilhelm J, Chang CT, Thackara J, **Frye RF**. Pharmacokinetics of nalmefene in pediatric patients during prophylaxis for epidural narcotics. *Pharmacotherapy* 2000; 20(7):745-749.
30. \*Alkharfy KM, Kellum JA, **Frye RF**, Matzke GR. Effect of Ceftazidime on Systemic Cytokine Concentrations in Rats. *Antimicrob Agents Chemother* 2000 Nov;44(11):3217-3219.
31. Hutzler JM, **Frye RF**, Tracy TS. Sensitive and specific high-performance liquid chromatography assay for 4'-hydroxyflurbiprofen and flurbiprofen in urine and plasma. *J Chromatogr B* 2000; 749:119-125.
32. Manley HJ, Bailie GR, **Frye RF**, McGoldrick MD. Pharmacokinetics of intermittent intravenous piperacillin in patients treated with automated peritoneal dialysis. *Perit Dial Int* 2000; 20:686-94.
33. Branch RA, Adedoyin A, **Frye RF**, Wilson J, Romkes M. In vivo modulation of CYP enzymes by quinidine and rifampin. *Clin Pharmacol Ther* 2000; 68:401-11.
34. \*Dowling TC, **Frye RF**, Fraley DS, Matzke GR. Characterization of tubular functional capacity in man using PAH and famotidine. *Kidney Int* 2001; 59:295-303.
35. \*Alkharfy KM, **Frye RF**. High-performance liquid chromatographic assay for acetaminophen glucuronide in human liver microsomes. *J Chromatogr B* 2001; 753:303-8.
36. Sowinski KM, Mueller BA, Grabe DW, Manley HJ, **Frye RF**, Bailie GR, and Marx MA. Cefazolin Dialytic Clearance by High-Efficiency and High-Flux Hemodialyzers. *Am J Kidney Dis* 2001;37(4):766-776.
37. Hutzler JM, **Frye RF**, Korzekwa KR, Branch RA, Huang SM, Tracy TS. In vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone. *Eur J Pharm Sci* 2001 Aug; 14(1):47-52.
38. Manley HJ, Bailie GR, **Frye RF**, McGoldrick MD. Intravenous vancomycin pharmacokinetics in automated peritoneal dialysis patients. *Perit Dial Int* 2001; 21(4): 378-85.
39. **Frye RF**, Branch RA. Effect of chronic disulfiram administration on activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects. *Br J Clin Pharmacol* 2002; 53:155-162.
40. \*Nolin TD, \*Colaizzi IV, Palevsky PM, Matzke GR, and **Frye RF**. Rapid Microtiter Plate Assay for Determination of Inulin in Human Plasma and Dialysate. *J Pharm Biomed Anal* 2002;28:209-215.
41. \*Alkharfy KM, **Frye RF**. Sensitive HPLC-fluorescence method for the determination of estradiol-3 and 17 glucuronides in rat and human liver microsomes. *J Chromatogr B* 2002; 774:33-38.
42. Zemaitis M, Poloyac S, **Frye R**. Identification of omega hydroxy fatty acids in biological samples as their pentafluoropropyl derivatives by gas chromatography/mass spectrometry with positive and negative ion detection. *Rapid Commun Mass Spectrom* 2002; 16: 1411-15.
43. \*Islam M, **Frye RF**, Richards TJ, Sbeitan I, Donnelly SS, Glue P, Agarwala SS, Kirkwood JM. Differential Effect of Interferon Alfa-2b (IFN $\alpha$ 2b) on the Cytochrome P450 Enzyme System: A Potential Basis of IFN Toxicity and its Modulation by Other Drugs. *Clin Cancer Res* 2002;8(8): 2480-7.
44. Solai LK, Pollock BG, Mulsant BH, **Frye RF**, Miller M, Sweet R, Kirshner M, Sorisio D, Begley A, and Reynolds CF. Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients. *J Clin Psychopharmacol* 2002; 22: 481-6.

45. **Frye RF**, Schneider VM, Frye CS, Feldman AM. Plasma levels of TNF- $\alpha$  and IL-6 are inversely related to cytochrome P<sub>450</sub>-dependent drug metabolism in patients with congestive heart failure. *J Card Failure* 2002; 8(5):315-9.
46. \*Lee JI, Chaves-Gnecco D, Amico JA, Kroboth PD, Wilson JW, **Frye RF**. Application of semisimultaneous midazolam administration for hepatic and intestinal CYP<sub>3A</sub> phenotyping. *Clin Pharmacol Ther* 2002;72:718-28.
47. \*Nolin TD, **Frye RF**. Stereoselective determination of the CYP<sub>2C19</sub> probe drug mephenytoin in human urine by gas chromatography mass spectrometry. *J Chromatogr B* 2003; 783:265-271.
48. Lee CR, Pieper JA, **Frye RF**, Hinderliter AL, Blaisdell JA, Goldstein JA. Tolbutamide, Flurbiprofen and Losartan as Probes of CYP<sub>2C9</sub> Activity in Humans. *J Clin Pharmacol* 2003;43:84-91.
49. Kroboth PD, Amico JA, Stone RA, Folan MM, **Frye RF**, Kroboth FJ, Bigos KL, Fabian TJ, Linares AM, Pollock BG, Hakala C. Influence of DHEA Administration on 24-Hour Cortisol Concentrations. *J Clin Psychopharmacol* 2003; 23(1):96-99.
50. Chalon SA, Desager JP, DeSante KA, **Frye RF**, Witcher J, Long AJ, Sauer JM, Golnez JL, Smith BP, Thomasson HR, Horsmans Y. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. *Clin Pharmacol Ther*. 2003 Mar;73(3):178-191.
51. Lee CR, Pieper JA, **Frye RF**, Hinderliter AL, Blaisdell JA, Goldstein JA. Flurbiprofen Metabolism in CYP<sub>2C9</sub>\*1 Heterozygotes. *Eur J Clin Pharmacol* 2003; 58(12):791-4.
52. Carcillo JA, Doughty L, Kofos D, **Frye RF**, Kaplan SS, Sasser H, Burckart GJ. Cytochrome P<sub>450</sub> mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure. *Intensive Care Med*. 2003; Jun;29(6):980-4.
53. Carcillo JA, Adedoyin A, Burckart GJ, **Frye RF**, Venkataramanan R, Knoll C, Thummel K, Roskos L, Wilson JW, Sereika S, Romkes M, Bebia Z, Branch RA. Coordinated Intrahepatic and Extrahepatic Regulation of CYP<sub>2D6</sub> in Health and Following Liver Transplantation. *Clin Pharmacol Ther* 2003; 73: 456-67.
54. \*Bolcato CA, **Frye RF**, Poloyac SM. Determination of 20-hydroxyeicosatetraenoic acid (20-HETE) in microsomal incubates using high-performance liquid chromatography–mass spectrometry (HPLC-MS). *J Chromatogr B* 2003; 794:363-372.
55. \*Dix J, Weber RJ, **Frye RF**, Nolin TD, Mrvos R, Krenzelok E. Stability of atropine sulfate prepared for mass chemical terrorism. *Journal of Toxicology - Clinical Toxicology* 2003; 41(6):771-775.
56. \*Nolin TD, Gastonguay MR, Bies RR, Matzke GR, **Frye RF**. Impaired 6-Hydroxychlorzoxazone elimination in patients with kidney disease: implication for CYP<sub>2E1</sub> pharmacogenetic studies. *Clin Pharmacol Ther* 2003; 74(6):555-568.
57. \*Hruska MW, **Frye RF**. Simplified method for determination of rosiglitazone in human plasma. *J Chromatogr B* 2004; 803:317-20.
58. Komoroski BJ, Zhang S, Cai H, Hutzler JM, **Frye R**, Tracy TS, Strom SC, Lehmann T, Ang, Yan CY, Cui Y, Venkataramanan R. Induction and inhibition of cytochromes P<sub>450</sub> by the St. John's wort constituent hyperforin in human hepatocyte cultures. *Drug Metab Dispos* 2004 May;32(5):512-8.
59. Poloyac SM, Tortorici MA, Przychodzin DI, Reynolds RB, Xie W, **Frye RF**, Zemaitis MA. The effect of isoniazid on CYP<sub>2E1</sub> and CYP<sub>4A</sub> mediated hydroxylation of arachidonic acid in the rat liver and kidney. *Drug Metab Dispos* 2004 July; 32(7):727-33.
60. \*Hruska MW, **Frye RF**. Determination of trimethoprim in low-volume human plasma by liquid chromatography. *J Chromatogr B* 2004; 807:301-5.
61. **Frye RF**, \*Fitzgerald SM, Lagattuta TF, \*Hruska MW, Egorin MJ. Effect of St. John's wort on imatinib mesylate pharmacokinetics. *Clin Pharmacol Ther* 2004; 76:323-9.

62. Elwell RJ, Volino LR, **Frye RF**. Stability of Cefepime in Icodextrin Peritoneal Dialysis Solution. *Ann Pharmacother* 2004; 38(12):2041-4.
63. \*Hruska MW, **Frye RF**, Langaee TY. A Pyrosequencing Method for Genotyping Cytochrome P<sub>450</sub> 2C8 and 2C9 Enzymes. *Clin Chem* 2004; 50(12):2392-5.
64. Bebia Z, Buch SC, Wilson JW, **Frye RF**, Romkes M, Cecchetti A, Chaves-Gnecco D, Branch RA. Bio-equivalence revisited: Influence of age and sex on CYP enzymes. *Clin Pharmacol Ther* 2004; 76:618-27.
65. \*Hruska MW, Amico JA, Langaee TY, Ferrell RE, Fitzgerald SM, **Frye RF**. The Effect of Trimethoprim on CYP<sub>2C8</sub> Mediated Rosiglitazone Metabolism in Human Liver Microsomes and Healthy Subjects. *Br J Clin Pharmacol* 2005; 59:70-9.
66. Harbrecht BG, **Frye RF**, Zenati MS, Branch RA, Peitzman AB. Cytochrome P-450 activity is differentially altered in severely injured patients. *Crit Care Med* 2005 Mar; 33(3):541-6.
67. Liu S, **Frye RF**, Branch RA, Venkataramanan R, Fung J, Burckart GJ. Changes in CYP<sub>450</sub> enzyme activity over time following liver transplantation. *J Clin Pharmacol*. 2005 Jun; 45(6):666-73.
68. Elwell RJ, **Frye RF**, Bailie GR. Pharmacokinetics of intraperitoneal cefepime in automated peritoneal dialysis. *Perit Dial Int* 2005 Jul-Aug; 25:380-6.
69. Elwell RJ, Manley HJ, **Frye RF**, Bailie GR. Pharmacokinetics of intraperitoneal cefazolin and ceftazidime coadministered to CAPD Patients. *Int J Artif Organs* 2005; 28(8):808-16.
70. Haas CE, Brazeau D, Cloen D, Booker BM, Frerichs V, Zaranek C, **Frye RF**, Kufel T. Cytochrome P-450 mRNA expression in peripheral blood lymphocytes as a predictor of enzyme induction. *Eur J Clin Pharmacol* 2005; 61(8):583-93.
71. **Frye RF**, \*Zgheib NK, Matzke GR, Chaves-Gnecco D, Rabinovitz M, Shaikh OS, Branch RA. Liver disease selectively modulates cytochrome P<sub>450</sub>-mediated metabolism. *Clin Pharmacol Ther* 2006; 80:235-45.
72. \*Zgheib NK, **Frye RF**, Tracy TS, Romkes M, Branch RA. Validation of incorporating flurbiprofen into the Pittsburgh cocktail. *Clin Pharmacol Ther* 2006; 80:257-63. PMID: 16952492.
73. O'Connell MB, **Frye RF**, Matzke GR, St. Peter JV, Willhite LA, Welch MR, Kowal P, LaValleur J. Effect of conjugated equine estrogens on oxidative metabolism in middle-age and elderly postmenopausal women. *J Clin Pharmacol* 2006; 46(11):1299-307. PMID: 17050794.
74. Blowey DL, Warady BA, Abdel-Rahman S, **Frye RF**, Manley HJ. Vancomycin disposition following intraperitoneal administration in children receiving peritoneal dialysis. *Perit Dial Int* 2007; 27(1):79-85.
75. \*Alkharfy KM, **Frye RF**. Effect of valerian, valerian/hops extracts, and valerenic acid on glucuronidation in vitro. *Xenobiotica* 2007; 37:113-23. PMID: 17484515.
76. \*Zgheib NK, **Frye RF**, Tracy TS, Romkes M, Branch RA. Evaluation of flurbiprofen urinary ratios as in vivo indexes for CYP<sub>2C9</sub> activity. *Br J Clin Pharmacol* 2007; 63(4):477-87. PMID: 17054666.
77. \*Dravid PV, **Frye RF**. Determination of N-desethylamodiaquine by hydrophilic interaction liquid chromatography with tandem mass spectrometry: application to in vitro drug metabolism studies. *J Chromatogr B* 2008; 863: 129-34. PMID: 18255358.
78. Johnson JA, Moore MJ, Shin J, **Frye RF**. Fostering PharmD student interest in research through a formalized summer research training program. *Am J Pharm Educ* 2008;72(2):23.1-6. PMID: 18483591.
79. \*Mohamed MF, \*Harvey SS, **Frye RF**. Determination of mycophenolic acid phenolic glucuronide in microsomal incubates using high performance liquid chromatography-tandem mass spectrometry. *J Chromatogr B* 2008; 870:251-4. PMID: 18602350.
80. \*Shin J, Pauly DF, Johnson JA, **Frye RF**. Simplified method for determination of clarithromycin in human plasma using protein precipitation in a 96-well format and liquid chromatography tandem mass spectrometry. *J Chromatogr B* 2008; 871:130-4. PMID: 18639501.
81. Pacanowski M, **Frye RF**, \*Enogie O, Schofield RS, Zineh I. Plasma coenzyme Q<sub>10</sub> predicts lipid-lowering response to high-dose atorvastatin. *J Clin Lipidol* 2008; 2:289-97. PMID: 19649137.

82. \*Mohamed MF, **Frye RF**, Langaee TY. Inter-population variation frequency of human inosine 5'-monophosphate dehydrogenase type II (IMPDH2) genetic polymorphisms. *Genetic Testing* 2008;12: 513-6. PMID: 18976158.
83. \*Alkharfy KM, Poloyac SM, Congiu M, Desmond PV, **Frye RF**. Effect of the acute phase response induced by endotoxin administration on the expression and activity of UGT isoforms in rats. *Drug Metab Lett.* 2008;2(4):248-55. PMID: 19356101.
84. Kim KM, Henderson GN, **Frye RF**, Galloway CD, Browne NJ, Segal MS, Imaram W, Angerhoferd A, Johnson RJ. Simultaneous determination of uric acid metabolites allantoin, 6-aminouracil, and triuret in human urine using liquid chromatography-mass spectrometry. *J Chromatogr B* 2009 Jan; 877: 65-70. PMID: 19081307.
85. \*Vanachayangkul P, Butterweck V, **Frye RF**. Determination of visnagin in rat plasma by liquid chromatography with tandem mass spectrometry and its application to in vivo pharmacokinetic studies. *J Chromatogr B* 2009 Mar 1;877(7):653-6. PMID: 19188097.
86. Kim KM, Henderson GN, Ouyang X, **Frye RF**, Sautin YY, Feig DI, Johnson RJ. A sensitive and specific liquid chromatography-tandem mass spectrometry method for the determination of intracellular and extracellular uric acid. *J Chromatogr B* 2009 Jul; 877: 2032-8. PMID: 19520625.
87. Elewa HF, Kozak A, **Frye RF**, Johnson MH, Ergul A, Fagan SC. Early atorvastatin reduces hemorrhage after acute cerebral ischemia in diabetic rats. *J Pharmacol Exper Ther* 2009 Aug; 330:532-40. PMID: 19478137.
88. Butterweck V, \*Zdrojewski I, Galloway C, **Frye R**, Derendorf H. Toxicological and pharmacokinetic evaluation of concomitant intake of grapefruit juice and simvastatin in rats after repeated treatment over 28 days. *Planta Med.* 2009 Sep;75(11):1196-202. PMID: 19350484.
89. \*Woelkart K, **Frye RF**, Derendorf H, Bauer R, Butterweck V. Pharmacokinetics and tissue distribution of Dodeca-2E,4E,8E,10E/Z-tetraenoic Acid Isobutylamides after oral administration in rats. *Planta Med.* 2009 Oct; 75(12):1306-13. PMID: 19399718.
90. Nolin TD, **Frye RF**, Le P, Sadr H, Naud J, Leblond FA, Pichette V, Himmelfarb J. Kidney disease alters nonrenal drug clearance by inhibiting transporter function. *J Am Soc Nephrol* 2009; 20: 2269-76. PMID: 19696225.
91. \*Stanton ML, Joy MS, **Frye RF**. Validation and application of a liquid chromatography-tandem mass spectrometric method for quantification of the drug transport probe fexofenadine in human plasma using 96-well filter plates. *J Chromatogr B* 2010; 878:497-501. PMID: 20045385.
92. \*Mohamed MF, **Frye RF**. Inhibition of intestinal and hepatic glucuronidation of mycophenolic acid by Ginkgo biloba extract and flavonoids. *Drug Metab Dispos* 2010; 38:270-5. PMID: 19889883.
93. Joy MS, **Frye RF**, Stubbart K, Falk RJ, Brouwer KR, Kharasch E. Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases. *J Clin Pharmacol* 2010 Jun;50(6):714-20. PMID: 20103693.
94. Navare HA, **Frye RF**, Cooper-DeHoff RM, Shuster JJ, Hall K, Schmidt SOF, Turner ST, Johnson JA. Atenolol exposure and risk for development of adverse metabolic effects. *Pharmacother Sep* 2010;30:872-8. PMID: 20795842.
95. \*Mohamed MF, \*Tseng T, **Frye RF**. Inhibitory effects of commonly used herbal extracts on UGT1A1 enzyme activity. *Xenobiotica* 2010 Oct;40(10):663-9. PMID: 20666626.
96. Gilbertson R, **Frye RF**, Nixon SJ. Nicotine as a factor in stress responsiveness among detoxified alcoholics. *Alcohol Alcohol.* 2011 Jan-Feb;46(1):39-51. PMID: 21045074.
97. \*Li L, Brunner I, Han AR, Hamburger M, Kinghorn AD, **Frye R**, Butterweck V. Pharmacokinetics of  $\alpha$ -mangostin in rats after intravenous and oral application. *Mol Nutr Food Res.* 2011 May;55 Suppl 1:S67-74. PMID: 21254395.



98. \*Mohamed MF, **Frye RF**. Inhibitory Effects of commonly used herbal extracts on UGT1A4, 1A6, and 1A9 enzyme activities. *Drug Metab Dispos* 2011; 39(9):1522-8. PMID: 21632963. PMCID: PMC3164271.
99. Ardjomand-Woelkart K, Kollroser M, Magnes C, Sinner F, **Frye RF**, Derendorf H, Bauer R, Butterweck V. Absolute/relative Bioavailability and Metabolism of Dodeca-2E,4E,8E,10E/Z-tetraenoic acid isobutylamides ("tetraenes") After Intravenous and Oral Single Doses to Rats. *Planta Med*. 2011;77(16):1794-9. PMID: 21604240.
100. Shin J, Pauly DF, Pacanowski MA, Langaee T, **Frye RF**, Johnson JA. Effect of CYP3A5 genotype on atorvastatin pharmacokinetics and interaction with clarithromycin. *Pharmacother* 2011;31:942-50. PMID: 21950641. PMCID: PMC3712822.
101. Flaherty KT, Lathia C, **Frye RF**, Schuchter L, Redlinger M, Rosen M, O'Dwyer PJ. Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: A phase I/II pharmacokinetic interaction study. *Cancer Chemother Pharmacol*. 2011 Nov;68(5):1111-8. PMID: 21350850.
102. \*Le MT, **Frye RF**, Rivard CJ, Cheng J, McFann KK, Segal MS, Johnson RJ, Johnson JA. Effects of high fructose corn syrup and sucrose on the pharmacokinetics of fructose and acute metabolic responses in healthy subjects. *Metabolism*. 2012 May;61(5):641-51. PMID: 22152650.
103. Joy MS, La M, Wang J, Bridges AS, Hu Y, Hogan SL, **Frye RF**, Blaisdell J, Goldstein JA, Dooley MA, Brouwer KLR, Falk RJ. Cyclophosphamide and 4-Hydroxycyclophosphamide Pharmacokinetics in Patients with Glomerulonephritis Secondary to Lupus and Small Vessel Vasculitis. *Br J Clin Pharmacol* 2012; 74(3):445-455. PMID: 22380717. PMCID: PMC3477346.
104. \*Sampath C, Haug K, Thanei S, Hamburger M, Derendorf H, **Frye R**, Butterweck V. Pharmacokinetics of valerenic acid in rats after intravenous and oral administrations. *Planta Med*. 2012 Apr;78(6):575-81. PMID: 22411722.
105. \*Karunathilake NP, **Frye RF**, Stavropoulos MF, Herman MA, Hastie BA. A Preliminary Study on the Effects of Self-Reported Dietary Caffeine on Pain Experience and Post-Operative Analgesia. *Journal of Caffeine Research* 2012; 2(4): 159-166.
106. Wikoff WR, **Frye RF**, Zhu H, Gong Y, Boyle S, Churchill E, Cooper-Dehoff RM, Beitelshes AL, Chapman AB, Fiehn O, Johnson JA, Kaddurah-Daouk R. Pharmacometabolomics reveals racial differences in response to atenolol treatment. 2013; PLoS ONE 8(3): e57639. doi:10.1371/journal.pone.0057639. PMID: 23536766.
107. \*Li L, Han AR, Kinghorn AD, **Frye RF**, Derendorf H, Butterweck V. Pharmacokinetic properties of pure xanthenes in comparison to a mangosteen fruit extract in rats. *Planta Med*. 2013; 79(8):646-53. doi: 10.1055/s-0032-1328543. PMID: 23673465.
108. Joy MS, **Frye RF**, Nolin TD, Roberts BV, La MK, Wang J, Brouwer KL, Dooley MA, Falk RJ. In Vivo Alterations in Drug Metabolism and Transport Pathways in Patients with Chronic Kidney Diseases. *Pharmacotherapy*. 2014;34(2):114-22. doi: 10.1002/phar.1347. PMID: 24038489.
109. Cooper-DeHoff RM, Hou W, Baillie RA, Beitelshes AL, Gong Y, Shaheen MH, Turner ST, Chapman AB, Gums JG, Boyle SH, Zhu H, Wikoff WR, Boerwinkle E, Fiehn O, **Frye RF**, Kaddurah-Daouk R, Johnson JA. Is a Diabetes-Linked Amino Acid Signature Associated with Beta Blocker-Induced Impaired Fasting Glucose? *Circ Cardiovasc Genetics*. 2014;7(2):199-205. doi: 10.1161/CIRCGENETICS.113.000421. PMID: 24627569.
110. \*Kawaguchi-Suzuki M, **Frye RF**, Zhu HJ, Brinda BJ, Chavin KD, Bernstein HJ, Markowitz JS. The effects of Milk Thistle (*Silybum marianum*) on human cytochrome P450 activity. *Drug Metab Dispos*. 2014 Oct;42(10):1611-6. doi: 10.1124/dmd.114.057232. PMID: 25028567.

111. \*Kawaguchi-Suzuki M, Bril F, Portillo Sanchez P, Cusi K, **Frye RF**. A validated liquid chromatography tandem mass spectrometry method for simultaneous determination of pioglitazone, hydroxypioglitazone, and ketopioglitazone in human plasma and its application to a clinical study. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2014;969:219-223. doi: 10.1016/j.jchromb.2014.08.019. PMID: 25195022.
112. \*Albassam AA, Mohamed MF, **Frye RF**. Inhibitory effect of six commonly used herbal extracts on CYP2C8 Enzyme activity. *Xenobiotica* 2015; 45(5):406-12. PMID: 25430798.
113. Weng L, Quinlivan E, Gong Y, Beitelshes AL, Shahin MH, Turner ST, Chapman AB, Gums JG, Johnson JA, **Frye RF**, Garrett TJ, Cooper-DeHoff RM. Association of Branched and Aromatic Amino Acid Levels with Metabolic Syndrome and Impaired Fasting Glucose in Hypertensive Patients. *Metab Syndr Relat Disord.* 2015 Jun; 13(5):195-202. doi: 10.1089/met.2014.0132. PMID: 25664967.
114. Rotroff DM, Shahin M, Gurley SB, Zhu H, Motsinger-Reif A, Meisner M, Beitelshes AL, Fiehn O, Johnson JA, Elbadawi-Sidhu M, **Frye RF**, Gong Y, Weng L, Cooper-DeHoff L, Rima Kaddurah-Daouk. Pharmacometabolomic Assessments of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response Phenotypes. *CPT: Pharmacometrics & Systems Pharmacology.* 2015 Nov;4(11):669-79. doi: 10.1002/psp4.12017. PMID: 26783503.
115. de Oliveira FA, Shahin MH, Gong Y, McDonough CW, Beitelshes AL, Gums JG, Chapman AB, Boerwinkle E, Turner ST, **Frye RF**, Fiehn O, Kaddurah-Daouk R, Johnson JA, and Cooper-DeHoff RM. Novel Plasma Biomarker of Atenolol-Induced Hyperglycemia Identified Through a Metabolomics-Genomics Integrative Approach. *Metabolomics* 2016 Aug; 12:129. PMID: 28217400.
116. Shahin MH, Gong Y, McDonough CW, Rotroff DM, Beitelshes AL, Garrett T, Gums JG, Motsinger-Reif A, Chapman AB, Turner ST, Boerwinkle E, **Frye RF**, Johnson JA, Fiehn O, Cooper-DeHoff R, and Kaddurah-Daouk R. A Genetic Response Score for Hydrochlorothiazide use: Insights from Genomics and Metabolomics Integration. *Hypertension* 2016 Sep;68(3):621-9. PMID: 27381900.
117. Weng L, Gong Y, Culver J, Gardell SJ, Petucci C, Morse AM, **Frye RF**, Turner ST, Chapman A, Boerwinkle E, Gums J, Beitelshes AL, Borum PR, Johnson JA, Garrett TJ, McIntyre LM, Cooper-DeHoff RM. Presence of arachidonoyl-carnitine is associated with adverse cardiometabolic responses in hypertensive patients treated with atenolol. *Metabolomics (Los Angel).* 2016 Oct;12(10). pii: 160. doi: 10.1007/s11306-016-1098-2. PubMed PMID: 28217401; PubMed Central PMCID: PMC5313050.
118. Voils SA, Lemon SJ, Jordan J, Riley P, **Frye R**. Early thrombin formation capacity in trauma patients and association with venous thromboembolism. *Thromb Res.* 2016 147:13-15. doi: [10.1016/j.thromres.2016.09.024](https://doi.org/10.1016/j.thromres.2016.09.024). PMID: 27664391.
119. Roederer MW, Kuo GM, Kisor DF, **Frye RF**, Hoffman JM, Jenkins J, Weitzel KW. Pharmacogenomics Competencies in Pharmacy Practice: A Blueprint for Change. *J Am Pharm Assoc (2003).* 2017 Jan - Feb;57(1):120-125. doi: [10.1016/j.japh.2016.08.014](https://doi.org/10.1016/j.japh.2016.08.014). PMID: 27816542.
120. \*Kawaguchi-Suzuki M, Nasiri-Kenari N, Shuster J, Gmitter F, Cancalon P, de Oliveira F, Kight J, Handberg E, Pepine C, **Frye RF**, and Cooper-DeHoff R. Effects of Low Furanocoumarin Hybrid Grapefruit Juice Consumption on Midazolam Pharmacokinetics. *J Clin Pharmacol.* 2017 57(3):305-311. doi: [10.1002/jcph.807](https://doi.org/10.1002/jcph.807). PMID: 27503364.
121. \*Albassam AA, **Frye RF**, Markowitz JS. The effect of milk thistle (*Silybum marianum*) and its main flavonolignans on CYP2C8 enzyme activity in human liver microsomes. *Chem Biol Interact.* 2017;271:24-29. doi: [10.1016/j.cbi.2017.04.025](https://doi.org/10.1016/j.cbi.2017.04.025). PMID: 28457856.
122. \*Kawaguchi-Suzuki M, Bril F, Kalavalapalli S, Cusi K, **Frye RF**. Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis. *Aliment Pharmacol Ther.* 2017;46(1):56-61. doi: [10.1111/apt.14111](https://doi.org/10.1111/apt.14111). PMID: 28470881.

123. Shahin MH, Gong Y, **Frye RF**, Rotroff DM, Beitelshes AL, Baillie RA, Chapman AB, Gums JG, Turner ST, Boerwinkle E, Motsinger-Reif A, Fiehn O, Cooper-DeHoff RM, Han X, Kaddurah-Daouk R, Johnson JA. Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics. *J Am Heart Assoc.* 2017 Dec 29;7(1). pii: e006656. doi:[10.1161/JAHA.117.006656](https://doi.org/10.1161/JAHA.117.006656). PMID: 29288159.
124. \*Li WY, Yu G, Hogan RM, Mohandas R, **Frye RF**, Gumprich E, Markowitz JS. Relative bioavailability of silybin A and silybin B from two multi-constituent dietary supplement formulations containing milk thistle extract: A single dose study. *Clin Ther* 2018 Jan;40(1):103-113.e1. PMID: 29273470. doi: [10.1016/j.clinthera.2017.11.013](https://doi.org/10.1016/j.clinthera.2017.11.013).
125. Voils SA, Shahin MH, Garrett TJ, **Frye RF**. Metabolomic association between venous thromboembolism in critically ill trauma patients and kynurenine pathway of tryptophan metabolism. *Thromb Res.* 2018 Mar 8;165:6-13. doi:[10.1016/j.thromres.2018.03.003](https://doi.org/10.1016/j.thromres.2018.03.003). PMID: 29544199.
126. Kalavalapalli S, Bril F, Koelmel J, Abdo K, Guingab J, Andrews P, Li WY, Jose D, Yost R, **Frye RF**, Garrett T, Cusi K, and Sunny N. Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis. *Am J Physiol Endocrinol Metab.* 2018 Aug 1;315(2):E163-E173. doi: [10.1152/ajpendo.00023.2018](https://doi.org/10.1152/ajpendo.00023.2018). PMID: 29634314.
127. \*Kawaguchi-Suzuki M, Cusi K, Bril F, Gong Y, Langaee T, and **Frye RF**. A genetic score associates with pioglitazone response in patients with non-alcoholic steatohepatitis. *Front Pharmacol*, 2018;9:752. doi:[10.3389/fphar.2018.00752](https://doi.org/10.3389/fphar.2018.00752). PMID: 30065651.
128. \*Albassam AA, **Frye RF**. Effect of pterostilbene on in vitro drug metabolizing enzyme activity. *Saudi Pharm J*, 2019; 27(3): 406-412. doi: [10.1016/j.jsps.2019.01.001](https://doi.org/10.1016/j.jsps.2019.01.001). PMID: 30976185.
129. Voils SA, Shoulders BR, Singh S, Solberg LM, Garrett TJ, **Frye RF**. Intensive Care Unit Delirium in Surgical Patients Is Associated with Upregulation in Tryptophan Metabolism. *Pharmacotherapy.* 2020;40(6):500-506. doi:[10.1002/phar.2392](https://doi.org/10.1002/phar.2392).
130. Thomas CD, Mosley SA, Kim S, Lingineni K, El Rouby N, Langaee T, Gong Y, Wang D, Schmidt SO, Binkley P, Estores DS, Feng K, Kim H, Kinjo M, Li Z, Chapman A, Cooper-DeHoff RM, Gums J, Hamadeh IS, Turner S, Zhao L, Schmidt S, **Frye RF**, Johnson JA, Cavallari LH. Examination of Metoprolol Pharmacokinetics and Pharmacodynamics across CYP2D6 Genotype-derived Activity Scores. *CPT Pharmacometrics Syst Pharmacol.* 2020 Dec;9(12):678-685. PMID: 33067866; PMCID: PMC7762806. doi: [10.1002/psp4.12563](https://doi.org/10.1002/psp4.12563).
131. Arwood MJ, McDonough CW, Cavallari LH, Elsey AR, **Frye RF**, Gong Y, Langaee T, Johnson JA, Wiisanen K. Evaluating an interactive teaching approach with personal genotyping to provide pharmacy students with a knowledge base for clinical pharmacogenetics. *J Am Coll Clin Pharm.* 2021;4:343-351. doi: [10.1002/jac5.1335](https://doi.org/10.1002/jac5.1335).
132. \*Mosley SA, Kim S, El Rouby N, Lingineni K, Vozmediano VE, Gong Y, Chen Y, Estores D, Feng K, Kim H, Kinjo M, Langaee T, Li Z, Schmidt SOF, Johnson JA, **Frye RF**, Lucy Lanyan F, Zhao L, Binkley PF, Schmidt S, Cavallari LH. A Randomized, Cross-over Trial of Metoprolol Succinate Formulations to Evaluate PK and PD Endpoints for Therapeutic Equivalence. *Clin Transl Sci.* 2022 Jul;15(7):1764-1775. doi: [10.1111/cts.13294](https://doi.org/10.1111/cts.13294). PMID: 35488487.
133. Markowitz JS, De Faria L, Zhang Q, Melchert PW, **Frye RF**, Klee BO, Qian Y. The Influence of Cannabidiol on the Pharmacokinetics of Methylphenidate in Healthy Subjects. *Med Cannabis Cannabinoids.* 2022 Nov 4;5(1):199-206. doi: [10.1159/000527189](https://doi.org/10.1159/000527189).

#### ABSTRACTS & SCIENTIFIC PRESENTATIONS:

\* = individuals in training are indicated by an asterisk

1. **Frye RF**, Marshall LL, Murphy JE, Goodhart GL. An evaluation of cefpirome use in adult patients with urinary tract infections. American Society of Hospital Pharmacists Midyear Clinical Meeting, Atlanta, GA. December, 1990.
2. Marshall LL, **Frye RF**, Murphy JE, Goodhart GL. Experiences in a phase III clinical trial: a student's perspective. American Society of Hospital Pharmacists Midyear Clinical Meeting, Atlanta, GA. December, 1990.
3. **Frye RF**, Job ML, Dretler RH. Teicoplanin nephrotoxicity: first case report. American College of Clinical Pharmacy Annual Meeting, San Francisco, CA. August, 1990. *Pharmacother* 1990;10:234.
4. Matzke GR, Carson SW, Millikin SP, **Frye RF**. The use of saliva concentrations to determine antipyrine pharmacokinetics in patients with various degrees of renal function. American Society for Clinical Pharmacology and Therapeutics, San Antonio, TX. March, 1991. *Clin Pharmacol Ther* 1991;49(2):171.
5. Matzke GR, Halstenson CE, **Frye RF**. An assessment of predicted vs. actual fractional drug removal by hemodialysis. Winter Practice and Research Forum of the American College of Clinical Pharmacy, Ft. Lauderdale, FL. February, 1991. *Pharmacother* 1991;11:106.
6. **Frye RF**, Carson SW, Matzke GR. Effect of type I diabetes mellitus and renal insufficiency on hepatic P<sub>450</sub> oxidative metabolism. Winter Practice and Research Forum of the American College of Clinical Pharmacy, Ft. Lauderdale, FL. February, 1991. *Pharmacother* 1991;11:96.
7. Matzke GR, **Frye RF**, Dupuis RE, Harris TG. Optimization of vancomycin Bayesian analysis: Initial population parameters (IPP) vs. forecasting programs. American College of Clinical Pharmacy Annual Meeting, Minneapolis, MN. August, 1991. *Pharmacother* 1991;11:267-8.
8. Matzke GR, **Frye RF**, Carson SW, Venkataramanan R, Jelliffe RW. Utility of antipyrine (AP) population pharmacokinetic parameters (PPP) derived from subjects with normal and impaired hepatic function (IHF) to predict AP pharmacokinetics in subjects with renal insufficiency. American Association of Pharmaceutical Scientists Annual Meeting, Washington, D.C. November, 1991. *Pharm Research* 1991; 8(10):60 and *Pharmacother* 1991;11(6):P41.
9. Carson SW, **Frye RF**, Matzke GR. A micro HPLC assay for determination of antipyrine and its metabolites in human urine. American Association of Pharmaceutical Scientists Annual Meeting, Washington, D.C. November, 1991. *Pharm Research* 1991; 8(10):20.
10. Murphy JE, **Frye RF**, Erkan V, Fakhreddine F. Evaluating gentamicin dosing methods in premature and normal gestation neonates utilizing first dose pharmacokinetic data. American College of Clinical Pharmacology, September, 1991. *J Clin Pharmacol* 1991; 31:846.
11. Matzke GR, Halstenson CE, **Frye RF**. Hemodialysis clearance (CL<sub>hd</sub>) of aminoglycosides and cephalosporins. 31st Interscience Conference on Antimicrobial Agents and Chemotherapeutics, Chicago, IL. October, 1991 and encore presentation at Winter Practice and Research Forum of the American College of Clinical Pharmacy, Phoenix, AZ. February, 1992. *Pharmacother* 1992;11(6):P41.
12. **Frye RF**, Matzke GR, Carson SW, Cohen HJ, Pritchett ELC. Effect of age and gender on antipyrine disposition. American Society for Clinical Pharmacology and Therapeutics, Orlando, FL. March, 1992. *Clin Pharmacol Ther* 1992;51:174.
13. Matzke GR, **Frye RF**, Carson SW, Millikin SP, Lyon JA. The influence of type I and type II diabetes mellitus on antipyrine disposition. American Society for Clinical Pharmacology and Therapeutics, Orlando, FL. March, 1992. *Clin Pharmacol Ther* 1992;51:134.
14. **Frye RF**, Matzke GR, Adedoyin A, Stiff DD, Porter J, Kubisty C, Branch RA. Utility of a cocktail strategy in assessing *in vivo* hepatic drug metabolism. Gordon Research Conference on Drug Metabolism, Plymouth, NH. July, 1992.

15. Matzke GR, Comstock TJ, **Frye RF**, Gillikin S, Rault RM, Schwinghammer TL, Kirschbaum B. The pharmacokinetics of epoetin alfa (EPO) are nonlinear following low dose administration. American Society of Nephrology Annual Meeting, Baltimore, MD. November, 1992. J Amer Soc Neph 1992;3(3):428.
16. Matzke GR, **Frye RF**, \*Poloyac S. Pharmacodynamic modeling of erythropoietin (EPO) therapy. American Society of Nephrology Annual Meeting, Baltimore, MD. November, 1992. J Amer Soc Neph 1992;3(3):428. and encore presentation at American College of Clinical Pharmacy, Ft. Lauderdale, FL. February, 1993. Pharmacother 1993;12(6):504.
17. Matzke GR, \*Poloyac S, Rault RM, **Frye RF**. Effect of time, dose, and hematocrit on erythropoietin disposition. American Society of Nephrology Annual Meeting, Boston, MA. November, 1993. J Amer Soc Neph 1993;4(3):428.
18. **Frye RF**, Stiff DD, Matzke GR, Branch RA. A sensitive method for the simultaneous determination of caffeine and its dimethylxanthine metabolites in human serum, saliva, and plasma. American Association of Pharmaceutical Scientists Annual Meeting, Orlando, FL, November, 1993. Pharm Research 1993;10(10):S43.
19. **Frye RF**, Stiff DD, Matzke GR, Adedoyin A, Kubisty C, Branch RA. Pharmacokinetics of chlorzoxazone: an *in vivo* probe of cytochrome P<sub>450</sub>2E1 activity. American Association of Pharmaceutical Scientists Annual Meeting, Orlando, FL, November, 1993. Pharm Research 1993;10(10):S388.
20. **Frye RF**, Matzke GR, Stiff DD, Adedoyin A, Porter J, Kubisty C, Branch RA. Validation of a five drug cocktail for use in population phenotyping. American Association of Pharmaceutical Scientists Annual Meeting, Orlando, FL, November, 1993. Pharm Research 1993;10(10):S388 and encore presentation at American College of Clinical Pharmacy Annual Meeting, St. Louis, MO. July, 1994.
21. **Frye RF**, Matzke GR, Rabinovitz M, Schade RR. Establishment of a quantitative hepatic function monitoring program. American College of Clinical Pharmacy Annual Meeting, St. Louis, MO. July, 1994. Pharmacother 1994;14:38.
22. Matzke GR, **Frye RF**, Carson SW, Cohen HJ, Pritchett ELC. Disposition of antipyrine and its metabolites in healthy, elderly, non-smoking males and females. 1994 Annual Meeting of American Geriatrics Society/American Federation for Aging Research. Los Angeles, CA. May 21, 1994.
23. Schade R, Nelson F, Matzke GR, **Frye R**. Salivary Caffeine/Antipyrine Clearance: A non-invasive approach to hepatic functional capacity. American Gastroenterology Association. San Francisco, CA. September 18-19, 1994.
24. Nelson FA, **Frye R**, Matzke G, Schade RR. Caffeine / Antipyrine clearance: A better tool for assessment of hepatic functional capacity in patients with hepatitis C? Hepatology 1994;20(4):381.
25. Matzke GR, Comstock T, **Frye RF**, Weiner M, Carter W. Computerized bayesian pharmacodynamic modeling for erythropoietin dosage individualization. 27th Annual Meeting of the American Society of Nephrology. Orlando, FL. October, 1994. J Amer Soc Neph 1994;5(4):464 and encore presentation at American College of Clinical Pharmacy Annual Meeting, Washington, D.C. August, 1995.
26. Matzke GR, \*Alexander ACM, **Frye RF**, Reynolds R, Palevsky P, Johnston J, Whitman C, Dixon RB, Rault R. The effect of hemodialysis on the disposition of nalmefene and nalmefene glucuronide. 27th Annual Meeting of the American Society of Nephrology. Orlando, FL. October 26-29, 1994. J Amer Soc Neph 1994;5(4):499.
27. Adedoyin A, Mauro K, **Frye R**, Porter J, Branch RA. Selective modulation of specific metabolizing activities by chloroquine. American Society for Clinical Pharmacology and Therapeutics, San Diego, CA. March, 1995. Clin Pharmacol Ther 57(2):150.
28. Matzke GR, Karara A, Hayes P, **Frye RF**, Weaver ML, Rault R, Robinson WT. Effect of renal insufficiency on the pharmacokinetics of abecarnil. American Society for Clinical Pharmacology and Therapeutics, San Diego, CA. March, 1995. Clin Pharmacol Ther 1995;57(2):218.

29. Matzke GR, \*Alexander A, **Frye RF**, Reynolds R, Whitman C, Dixon R, Rault R. The disposition of nalmefene is significantly altered in patients with end-stage renal disease. American Society for Clinical Pharmacology and Therapeutics, San Diego, CA. March, 1995. Clin Pharmacol Ther 1995;57(2):218.
30. **Frye RF**, Mauro K, Adedoyin A, Matzke GR and Branch RA. Nonlinear pharmacokinetics of chlorzoxazone in humans. American Society for Clinical Pharmacology and Therapeutics, San Diego, CA. March, 1995. Clin Pharmacol Ther 1995;57: 217.
31. **Frye RF**, Matzke GR, Schade RR. Lack of correlation between Pugh score and quantitative measures of hepatic function in patients with hepatitis C. American College of Clinical Pharmacy Annual Meeting, Washington, DC. August, 1995 and Pharmacother 1995;15(3): 389-90.
32. **Frye RF**, Matzke GR, McVey JL, Reynolds R, Dixon R, Rabinovitz M, Schade RR. Effect of hepatic insufficiency on the pharmacokinetics of nalmefene. American College of Clinical Pharmacy Annual Meeting, Washington, DC. August, 1995 and Pharmacother 1995;15(3): 390.
33. \*Kelly PA, **Frye RF**, Burckart GJ, Lever J, Venkataramanan RV, Fung JJ, Matzke GR, Branch RA. Differential recovery of cytochrome P450 isozymes following orthotopic liver transplantation. American College of Clinical Pharmacy Annual Meeting, Washington, DC. August, 1995 and Pharmacother 1995;15(3): 396.
34. Adedoyin A, **Frye RF**, Matzke GR, Stiff DD, Branch RA. A model to study metabolic drug interaction *in vivo*: Use of a five drug cocktail. American Association of Pharmaceutical Scientists Annual Meeting, Miami, FL, November, 1995 and Pharm Research 1995;12(9):S373.
35. **Frye RF**, Matzke GR, Adedoyin A, Schade RR, Branch RA. Effect of liver disease on CYP activity assessed utilizing a cocktail approach. American Association of Pharmaceutical Scientists Annual Meeting, Miami, FL, November, 1995 and Pharm Research 1995;12(9):S380.
36. Matzke GR, \*Joy M, Palevsky P, **Frye R**, Johnston J, Greenberg A. Continuous venovenous hemodialysis clearance of vancomycin is highly membrane dependent. International Conference on Continuous Renal Replacement Therapies. San Diego, CA., November, 1995 and Blood Purif 1995;13:401.
37. Comstock TJ, Matzke GR, \*Joy MS, **Frye RF**, Dover T. Pharmacist training for an outcomes-based multicenter clinical trial. Thirtieth ASHP Midyear Clinical Meeting. Las Vegas, NV. December, 1995, and Int Pharmaceutical Abstracts 1995; 32:2405.
38. \*Alexander ACM, Matzke GR, **Frye RF**, Bruns F, Rault R. Differential response of serum iron indices (SII) to iron dextran (ID) in hemodialysis patients. American Society for Clinical Pharmacology and Therapeutics, Orlando, FL, March, 1996 and Clin Pharmacol Ther 1996;59: 155.
39. \*Kelly PA, **Frye RF**, Burckart GJ, Lever J, Venkataramanan RV, Fung JJ, Matzke GR, Branch RA. Differential CYP450 isozyme activity following orthotopic liver transplantation. American Society for Clinical Pharmacology and Therapeutics, Orlando, FL, March, 1996 and Clin Pharmacol Ther 1996;59: 136.
40. **Frye RF**, Matzke GR, \*Alexander ACM, Palevsky P, Rault R, Branch RA. Effect of renal insufficiency on CYP activity. American Society for Clinical Pharmacology and Therapeutics, Orlando, FL, March, 1996 and Clin Pharmacol Ther 1996;59: 155.
41. **Frye RF**, Matzke GR, Palevsky P, Rault R. Impaired 6-hydroxychlorzoxazone elimination in patients with renal insufficiency: Implication for pharmacogenetic studies. American Society for Clinical Pharmacology and Therapeutics, Orlando, FL, March, 1996 and Clin Pharmacol Ther 1996;59: 168.
42. \*Kelly PA, **Frye RF**, Burckart GJ, Venkataramanan R, Jain A, Fung JJ, Romkes M, Branch RA. Tacrolimus dosing in stable liver transplant (OLT) recipients correlates with phenotypic CYP3A4 enzyme activity but not leukocyte CYP3A4 mRNA expression. American Society of Transplant Physicians Annual Meeting, Dallas, TX, May, 1996.

43. Matzke GR, **Frye RF**, \*Joy M, Palevsky P. Continuous venovenous hemodialysis (CVVHD) clearance of ceftriaxone. 42nd Annual Conference with the Cardiovascular Science and Technology Conference Washington, DC. May 2-4, 1996, and ASAIO Journal 1996; 42(2):90.
44. Eibling DE, Romkes M, Adedoyin A, White C, **Frye R**, Johnson J, Branch RA. Evaluation of CYP2D6 genotype and phenotype in patients with head and neck cancer. Presented at the 4th International Conference on Head and Neck Cancer. Toronto, Ontario, Canada, July 1996.
45. \*Kelly PA, Burckart GJ, Zeevi A, Banas R, Pavlik M, **Frye RF**, Duquesnoy R, Venkataramanan R, Fung JJ. Immune modulating effects of ciprofloxacin on peripheral blood lymphocytes. American College of Clinical Pharmacy Annual Meeting, Nashville, TN. August, 1996.
46. Matzke GR, **Frye RF**, \*Joy MS, Palevsky P. Determinants of ceftriaxone clearance by CVVHD and CVVH. Annual Meeting of the American Society of Nephrology. New Orleans, LA., November 1996, and J Amer Soc Neph 1996; 7(9) 1521.
47. Matzke GR, \*Joy MS, **Frye RF**, Palevsky P. Clearance of ceftazidime by continuous venovenous hemofiltration (CVVH) and hemodialysis (CVVHD). Annual Meeting of the American Society of Nephrology. New Orleans, LA., November 1996, and J Amer Soc Neph 1996; 7(9) 1521.
48. \*Pecora PG, **Frye RF**, Ptachcinski RJ. Stability of omeprazole in alkaline solutions. ASHP Midyear Clinical Meeting. New Orleans, LA. December, 1996.
49. \*Berringer RA, **Frye RF**, Matzke GR. Clinical significance of vancomycin removal during high-flux hemodialysis. ASHP Midyear Clinical Meeting. New Orleans, LA. December, 1996.
50. Doughty L, Kaplan S, Burckart G, **Frye R**, Carcillo J. Cytochrome P<sub>450</sub> (P<sub>450</sub>) function is decreased in pediatric sepsis-induced multiple organ failure. Crit Care Med 1997;25(1):A125.
51. \*Dowling TD, **Frye RF**, Matzke GR, Fraley DS. Para-aminohippuric acid renal clearance after an intravenous bolus is not an accurate marker of effective renal plasma flow. American Society for Clinical Pharmacology and Therapeutics, San Diego, CA, March, 1997 and Clin Pharmacol Ther 1997;61: 215.
52. Romkes M, Adedoyin A, White C, **Frye R**, Johnson J, Eibling D, Branch R. Role of CYP and Phase II enzymes in head and neck cancer risk. Proc Am Assoc Cancer Res 1997;38:1452.
53. \*Dowling TD, **Frye RF**, Matzke GR, Fraley DS, Rabinovitz M. Reduced acetylation of para-aminohippuric acid in liver disease. American Society for Clinical Pharmacology and Therapeutics, San Diego, CA, March, 1997 and Clin Pharmacol Ther 1997;61: 215.
54. O'Connell MB, **Frye RF**, St. Peter JV, Matzke GR, La Valleur J. Effect of conjugated estrogen replacement therapy on CYP activity. American Society for Clinical Pharmacology and Therapeutics, San Diego, CA, March, 1997 and Clin Pharmacol Ther 1997;61: 226.
55. \*Dowling TC, **Frye RF**, Matzke GR, Fraley DS. Characterization of saturable renal elimination of para-aminohippurate (PAH) and its acetyl metabolite in man. 1997 Spring Practice and Research Forum. American College of Clinical Pharmacy. Panama City, FL. April 6-9, 1997.
56. \*Kearney B, **Frye RF**. Dextromethorphan as a CYP3A<sub>4/5</sub> probe: Evaluation of plasma-based phenotypic trait measures. Eastern States Residents Conference, May 1997.
57. Marx MA, **Frye RF**, Matzke GR, Golper TA. Cefazolin is efficacious for empiric treatment of hd-related infections. 15<sup>th</sup> meeting of the International Society of Blood Purification, 1997.
58. \*Kofos D, **Frye R**, Burckart G, Reyes J, Carcillo J. Drug metabolism in pediatric liver transplantation. Ped Res 1997;41(4):36A.
59. Doughty L, Kaplan S, Burckart G, **Frye R**, Carcillo J. Cytochrome P<sub>450</sub> function in pediatric sepsis-induced multiple organ failure. Ped Res 1997;41(4):32A.

60. **Frye RF**, Bertz RJ, Granneman GR, Qian J, Lamm J, Dennis S, Valdes J. Effect of ritonavir on the pharmacokinetics and pharmacodynamics of alprazolam. 37th Interscience Conference on Antimicrobial Agents and Chemotherapeutics, Toronto, Ontario, Can. September 1997.
61. Marx MA, **Frye RF**, Matzke GR, Golper TA. Cefazolin for empiric treatment of hd-related infections: efficacy and blood concentrations. 30th Annual Meeting of the American Society of Nephrology. San Antonio, TX. November, 1997. J Amer Soc Neph 1997;8:202A-3A.
62. Grabe DW, Bailie GR, **Frye RF**. Pharmacokinetics of intermittent intraperitoneal ceftazidime in CAPD patients with and without residual renal function. American College of Clinical Pharmacy Annual Meeting, Phoenix, AZ. November, 1997 and Pharmacother 1997;17(5): 1099.
63. \*Kofos D, **Frye R**, Burkcart G, Carcillo J. Diminished oxidative metabolizing capacity of specific cytochrome P<sub>450</sub> (P<sub>450</sub>) isozymes in sepsis induced pediatric multiple organ failure (MOF). Society of Critical Care Medicine Annual Meeting. Crit Care Med 1998;26(1):A79.
64. \*Dowling TC, **Frye RF**, Matzke GR, Fraley DS. Bolus administration of nonradiolabeled iothalamate (NRI) provides an accurate index of glomerular filtration rate (GFR). Seventh Annual Spring Clinical Nephrology Meeting, Nashville, TN. March 26-29, 1998, and Am J Kidney Dis 1998; 31: A14.
65. Adedoyin A, Trump DL, Brufsky A, **Frye RF**, Hofacker J, Branch RA. Selective alteration of specific metabolizing enzyme activities by disulfiram and ketoconazole. American Society for Clinical Pharmacology and Therapeutics, New Orleans, LA, March, 1998 and Clin Pharmacol Ther 1998;63:154.
66. **Frye RF**, Bertz RJ, Granneman GR, Lauva I, Lamm J, Dennis S, Valdes J. Effect of ritonavir on CYP1A<sub>2</sub>, 2C<sub>19</sub>, and 2E<sub>1</sub> activities in vivo. American Society for Clinical Pharmacology and Therapeutics, New Orleans, LA, March, 1998 and Clin Pharmacol Ther 1998;63:148; Encore Presentation 1998 ACCP Annual Meeting, Cincinnati, OH, November 1998.
67. \*Opatik LM, **Frye RF**, \*Campbell JA, Ptachcinski RJ, Shapiro R, Marsh JW. Valacyclovir bioavailability in kidney and liver transplant patients. Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA. September 1998; Encore Presentation 1998 ACCP Annual Meeting, Cincinnati, OH, November 1998.
68. \*Dowling TC, **Frye RF**, Fraley DS, Matzke GR. Tubular secretion of famotidine in man is not capacity limited. J Amer Soc Neph 1998; 9:69A.
69. \*Dowling TC, **Frye RF**, Fraley DS, Matzke GR. Validation of a sequential PAH infusion method to characterize anionic tubular secretion in man. 31st Annual Meeting of the American Society of Nephrology. Philadelphia, PA. November 1998 and J Amer Soc Neph 1998; 9:70A.
70. **Frye RF**, Kroboth PD, Linares AM, Folan MM, Hakala C, Stone R, Kroboth FJ. Gender differences in the pharmacokinetics of dehydroepiandrosterone following single and multiple-dose administration in healthy older adults. Presented at the 1998 Society for Neuroscience Annual Meeting, November 1998, Los Angeles, CA; Encore Presentation 1998 ACCP Annual Meeting, Cincinnati, OH, November 1998.
71. Folan M, Kroboth P, Stone R, **Frye R**, Kroboth F, Sweeney J. Endogenous dehydroepiandrosterone (DHEA), DHEA-S and saccadic eye movement (SEM) function in older adults. Presented at the 1998 Society for Neuroscience Annual Meeting, November 1998, Los Angeles, CA; Encore Presentation 1998 ACCP Annual Meeting, Cincinnati, OH, November 1998.
72. **Frye RF**. Evaluation of the selectivity of disulfiram inhibition on in vivo cytochrome P<sub>450</sub> activity. Presented at the 1998 ACCP Annual Meeting, Cincinnati, OH, November 1998 and Pharmacother 1998;18:1157.
73. \*Al-Kharfy K, Matzke GR, **Frye RF**, Kellum JA. Ceftazidime clearance in septic and non-septic rats receiving continuous arteriovenous hemofiltration (CAVH). Presented at the 1999 ACCP Spring Meeting, Orlando, FL.



74. \*Islam, M, Donnelly S, Kirkwood J, **Frye RF**. Differential effect of IFN ([alpha]-2b) on the CYP<sub>450</sub> enzyme system: a potential issue of ifn toxicity and its modulation by other drugs. Presented at the 1999 Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA., May 1999.
75. Burckart GJ, **Frye RF**, Branch RA, Venkataramanan R, McKaveney T, Hammond R, Rosenberg C, Fung JJ, Jain A. Drug metabolism in older OLTx patients: effects of donor and recipient age. Presented at the American Society of Transplant Physicians Annual Meeting, May, 1999.
76. Chaves-Gnecco DG, Branch RA, Cressman MD, **Frye RF**, Vyas SJ, Cannon YM, Pauli MM, Data JL, Ramu K, Daniell G. An open-label, crossover Phase I pharmacokinetics study of licostinel alone or in combination with probenecid in healthy volunteers. Presented at the American Association of Pharmaceutical Scientists Annual Meeting, New Orleans, LA, November, 1999.
77. Matzke GR, **Frye RF**, Nolin TD, Baritot DA, Palevsky PM. Vancomycin removal by low and high flux hemodialysis with polymethylmethacrylate dialyzers. Presented at the Annual Meeting of the American Society of Nephrology, November 1999 and J Amer Soc Neph 1999;10:193A.
78. Matzke GR, **Frye RF**, Nolin TD, Baritot DA, Palevsky PM. Cefazolin and ceftazidime clearance during hemodialysis with low and high flux polymethylmethacrylate dialyzers. Presented at the Annual Meeting of the American Society of Nephrology, November 1999 and J Amer Soc Neph 1999;10:193A.
79. Matzke GR, Nolin TD, **Frye RF**, Baritot DA, Palevsky PM. In vitro model for tobramycin disposition during hemodialysis with low and high flux biocompatible membranes. Presented at the Annual Meeting of the American Society of Nephrology, November 1999 and J Amer Soc Neph 1999;10:193A.
80. **Frye RF**, Tracy TS, Hutzler JM, Huang SM, Branch RA. Flurbiprofen as a selective in vivo probe of CYP<sub>2C9</sub> activity. Presented at the American Society for Clinical Pharmacology and Therapeutics, Los Angeles, CA, March, 2000 and Clin Pharmacol Ther 2000;67:109.
81. **Frye RF**, Kroboth PD, Folan MM, et al. Effect of DHEA on CYP<sub>3A</sub>-mediated metabolism of triazolam. Presented at the American Society for Clinical Pharmacology and Therapeutics, Los Angeles, CA, March, 2000 and Clin Pharmacol Ther 2000;67:109.
82. Wilson JW, **Frye RF**, Huang SM, Branch RA. Sample size effects in assessing gender population bioequivalence (GPB) in a Pittsburgh cocktail. Presented at the American Society for Clinical Pharmacology and Therapeutics, Los Angeles, CA, March, 2000 and Clin Pharmacol Ther 2000;67:116.
83. Hutzler JM, **Frye RF**, Korzekwa KR, Branch RA. Does dapsone-mediated activation of flurbiprofen metabolism by CYP<sub>2C9</sub> occur in vivo? Presented at the American Society for Clinical Pharmacology and Therapeutics, Los Angeles, CA, March, 2000 and Clin Pharmacol Ther 2000;67:134.
84. \*Alkharfy KM, **Frye RF**. Determination of acetaminophen glucuronide in human liver microsomes. Presented at the annual meeting of the International Society for the Study of Xenobiotics, October 2000 and Drug Metab Rev 2000; 32(suppl 2): 177.
85. Poloyac SM, Zemaitis MA, **Frye RF**. Cytochrome P<sub>450</sub> mediated arachidonic acid metabolism: tissue specific activity and alterations by endotoxin. Presented at the annual meeting of the International Society for the Study of Xenobiotics, October 2000. Drug Metab Rev 2000; 32(suppl 2): 220.
86. Matzke GR, Palevsky PM, **Frye RF**. In-vitro model for tobramycin disposition during hemodialysis with conventional and high flux biocompatible membranes. Presented at the American Society of Nephrology Annual Meeting, October, 2000.
87. Matzke GR, Palevsky PM, **Frye RF**. In-vitro model for ceftazidime disposition during hemodialysis with conventional and high flux biocompatible membranes. Presented at the American Association of Pharmaceutical Scientists Annual Meeting, November, 2000.
88. Muir K, **Frye RF**, Arumugham T, Sale M. Lack of effect of GW320659 on cytochrome P<sub>450</sub> (CYP<sub>450</sub>) activity. Presented at the American Society for Clinical Pharmacology and Therapeutics, Orlando, FL, March, 2001 and Clin Pharmacol Ther 2001; 69: P57.

89. Lathia CD, **Frye RF**, Ferry S, Yeh S, Sundaresan PR. Evaluation of CYP<sub>3A</sub>, CYP<sub>2C9</sub>, and CYP<sub>2C19</sub> enzyme induction in very early Phase I studies. Presented at the annual meeting of the American Society for Clinical Pharmacology and Therapeutics, Orlando, FL, March, 2001 and Clin Pharmacol Ther 2001; 69: P55.
90. \*Lee JI, Pauli M, Chaves-Gnecco D, Amico JA, Kroboth PD, **Frye RF**. Application of the semi-simultaneous bioavailability approach to CYP<sub>3A</sub> phenotyping with midazolam. Presented at the American Society for Clinical Pharmacology and Therapeutics, Orlando, FL, March, 2001 and Clin Pharmacol Ther 2001; 69: P39.
91. Jung LL, Zamboni WC, **Frye RF**, Johnson CS, Adedoyin A, Hofacker JK, Branch RA, and Trump DL. Modulation of all-trans-retinoic Acid (ATRA) disposition with ketoconazole and disulfiram in patients with hormone-refractory prostate cancer. Presented at the American Society for Clinical Oncology Annual Meeting, May 2001.
92. Palevesky PM, **Frye RF**, Matzke GR. Effect of dialyzer reprocessing on the clearance of low and intermediate molecular weight solutes. Thirty-fourth Annual meeting of the American Society of Nephrology. San Francisco, CA. October 2001, and J Am Soc Nephrol 2001.
93. Carson SW, Hill-Zabala CE, Hoyler SL, Kotlyar M, **Frye RF**, Golding M. Acute and chronic effects of St. John's wort (Hypericum Perforatum) on cytochromes P<sub>450</sub> enzyme activity in healthy volunteers. Presented at the 2001 Annual meeting of the American College of Clinical Pharmacy, Tampa, FL.
94. Bolcato CA, **Frye RF**, Zemaitis MA, Poloyac SM. Cytochrome P<sub>450</sub> mediated bioactivation of arachidonic acid in rat and human brain. Presented at the American Association of Pharmaceutical Scientists Annual Meeting, Denver, CO, October 2001.
95. \*Alkharfy KM, Poloyac SM, **Frye RF**. Effect of the acute-phase response on in vivo UGT activity in rats. Presented at the American Association of Pharmaceutical Scientists Annual Meeting, Denver, CO, October 2001.
96. Lee CR, Pieper JA, **Frye RF**, Hinderliter AL, Blaisdell JA, Goldstein JA. Consequences of CYP<sub>2C9</sub> polymorphisms on flurbiprofen pharmacokinetics. Presented at the American Society for Clinical Pharmacology and Therapeutics, Atlanta, GA, March 2002 and Clin Pharmacol Ther 2002; 71: 62.
97. Lee CR, Pieper JA, **Frye RF**, Hinderliter AL, Blaisdell JA, Goldstein JA. Assessment of CYP<sub>2C9</sub> phenotypic:genotypic relationships with potential probes. Presented at the American Society for Clinical Pharmacology and Therapeutics, Atlanta, GA, March 2002 and Clin Pharmacol Ther 2002; 71: 25.
98. Kroboth PD, Amico JA, Stone RA, Folan MM, **Frye RF**, Kroboth FJ, Bigos KL, Fabian TJ, Linares AM, Pollock BG, Hakala C. Influence of oral DHEA administration on 24-Hour cortisol concentrations in older women and men. 42nd Annual NCDEU Meeting, Boca Raton, FL, June 2002.
99. Matzke GR, Palevsky PM, **Frye RF**. In-vitro assessment of influence of molecular weight on drug clearance by conventional and synthetic dialyzers. J Clin Pharmacol 2002; 42 (9): 85.
100. \*Dix J, Weber RJ, **Frye RF**, Nolin TD, Mrvos R, Krenzelok E. Stability of atropine sulfate prepared for mass chemical terrorism. Presented at the North American Congress of Clinical Toxicology, September 2002.
101. Komoroski BJ, Zhang S, Cai HB, Hutzler JM, **Frye RF**, Tracy TS, Strom SC, Ang C, Cui YY, Venkataramanan R. The inductive effect of hyperforin (St. John's wort) predominates over the inhibitory potential of hyperforin at physiological concentrations. Presented at the annual meeting of the International Society for the Study of Xenobiotics, October 2002.
102. \*Nolin TD, Bies RR, Gastonguay MR, **Frye RF**. A model for the simultaneous description of the pharmacokinetics of chlorzoxazone and its primary metabolite 6-hydroxychlorzoxazone after a single oral dose. Presented at the American Association of Pharmaceutical Scientists Annual Meeting, Toronto, CA, November 2002.

103. Bolcato CA, **Frye RF**, Zemaitis MA, Poloyac SM. Quantification of 20-HETE, a vasoconstrictive cytochrome P<sub>450</sub> metabolite of arachidonic acid, by high performance liquid chromatography/electrospray mass spectrometry. Presented at the American Association of Pharmaceutical Scientists Annual Meeting, Toronto, CA, November 2002.
104. Elwell RJ, **Frye RF**, Ganchuk SR, Bailie GR. Pharmacokinetics of intraperitoneal cefepime in automated peritoneal dialysis. Presented at the Annual Dialysis Conference, Seattle, WA, March 2003.
105. Blowey DL, Warady BA, Manley HJ, **Frye RF**, Smith C. Vancomycin absorption after intraperitoneal administration in children receiving peritoneal dialysis. Presented at the American Society for Clinical Pharmacology and Therapeutics, Washington, DC, April 2003 and Clin Pharmacol Ther 2003; 73: P37.
106. Blowey DL, Warady BA, Manley HJ, **Frye RF**, Smith C. Pharmacokinetics of vancomycin in children receiving peritoneal dialysis. Presented at the American Society for Clinical Pharmacology and Therapeutics, Washington, DC, April 2003 and Clin Pharmacol Ther 2003; 73: P38.
107. \*Nolin TD, Gastonguay MR, Bies RR, Matzke GR, Bernardo JF, Aslam N, **Frye RF**. Population pharmacokinetic model of chlorzoxazone and 6-hydroxychlorzoxazone in renal failure: impact of patient covariates on CYP2E1 activity. Presented at the American Society for Clinical Pharmacology and Therapeutics, Washington, DC, April 2003 and Clin Pharmacol Ther 2003;73: P80.
108. **Frye RF**, Chaves-Gnecco D, Matzke GR, Rabinovitz M, Shakil AO, Branch RA. Selective modulation of CYP-mediated metabolism in liver disease. Presented at the American Society for Clinical Pharmacology and Therapeutics, Washington, DC, April 2003 and Clin Pharmacol Ther 2003;73: P28.
109. \*Hruska MW, Amico JA, **Frye RF**. Effect of CYP2C8 inhibition by trimethoprim on the pharmacokinetics of rosiglitazone. Presented at the American College of Clinical Pharmacology Annual Meeting, Tampa, FL, September 2003 and J Clin Pharmacol 2003;43:P1036.
110. Nicholas TM, Gastonguay MR, Sweeney KR, Nolin TD, **Frye RF**. Application of a map Bayesian method for CYP2E1 phenotyping. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Miami, FL, March 2004 and Clin Pharmacol Ther 2004;75:P41.
111. **Frye RF**, \*Fitzgerald SM, Lagattuta TF, Egorin MJ. Effect of St. John's wort on imatinib mesylate pharmacokinetics. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Miami, FL, March 2004 and Clin Pharmacol Ther 2004;75:P96.
112. Elwell RJ, Volino LR, **Frye RF**. Stability of Cefepime in Icodextrin Peritoneal Dialysis Solution. Presented at the 2004 Annual meeting of the American College of Clinical Pharmacy, Dallas, TX, October 2004 and Pharmacother 2004;24:1447.
113. Persky A, Moore K, Kim Y, Symonds W, Denning J, **Frye RF**. Effect of 695634, a Next Generation NNRTI, on Cytochrome P<sub>450</sub> (CYP) Probe Substrates. Presented at the 2004 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, October 2004.
114. \*Sivasubramanian R, **Frye RF**, Venkataramanan R. Components of valerian extracts and valerenic acid alter acetaminophen glucuronidation, in vitro. Presented at the American Association of Pharmaceutical Scientists Annual Meeting, Baltimore, MD, November 2004.
115. Liu S, **Frye R**, Branch R, Venkataramanan R, Fung J, Burckart G. Changes in CYP450 enzyme activity over time following liver transplantation. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Orlando, FL, March 2005 and Clin Pharmacol Ther 2005;77:P34.
116. \*Hruska MW, Cheong JA, Amico JA, Langaee TY, **Frye RF**. Effect of CYP2C8 genotype on rosiglitazone pharmacokinetics. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Orlando, FL, March 2005 and Clin Pharmacol Ther 2005;77:P35.
117. \*Hruska MW, Cheong JA, Langaee TY, **Frye RF**. Effect of St. John's wort administration on CYP2C8 mediated rosiglitazone metabolism. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Orlando, FL, March 2005 and Clin Pharmacol Ther 2005;77:P36.

118. \*Sivasubramanian R, **Frye RF**, Venkataramanan R. Valerian does not alter acetaminophen glucuronidation. Presented at the American Association of Pharmaceutical Scientists Annual Meeting, Nashville, TN, November 2005.
119. \*Price E, Galloway CD, **Frye RF**. Development of a rapid method for the determination of rosiglitazone in human plasma by liquid chromatography tandem mass spectrometry in a 96-well format: application to pharmacokinetic studies. Presented at the 19th Annual Research Showcase, College of Pharmacy, University of Florida, February 2006.
120. Zgheib N, **Frye R**, Tracy T, Romkes M, Branch R. Validation of incorporating flurbiprofen into the Pittsburgh cocktail. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Baltimore, MD, March 2006 and Clin Pharmacol Ther 2006;79:P46.
121. \*Dravid P, **Frye R**. Quantitative determination of chlorzoxazone in human plasma and urine by LC/MS/MS: application to CYP2E1 phenotyping studies. Presented at the American Association of Pharmaceutical Scientists Annual Meeting, San Antonio, TX, October 2006. AAPS Journal. 2006; 8(S2). Abstract W1063.
122. \*Karnes J, Galloway C, **Frye R**. The influence of CYP2C9 polymorphisms on *in vitro* metabolism of repaglinide. Presented at the 20th Annual Research Showcase, College of Pharmacy, University of Florida, February 2007.
123. \*Dravid P, **Frye R**. Determination of desethylamodiaquine by liquid chromatography tandem mass spectrometry: Application to cytochrome P<sub>450</sub> 2C8 studies in human liver microsomes. Presented at the 20th Annual Research Showcase, College of Pharmacy, University of Florida, February 2007.
124. \*Nolin TD, Matzke GR, \*Barker TJ, **Frye RF**. Effect of chronic kidney disease on Cytochrome P<sub>450</sub> 2C19 activity and 4-Hydroxymephenytoin urinary recovery. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Anaheim, CA, March 2007 and Clin Pharmacol Ther 2007;81:S56.
125. Hastie BA, Stavropoulos MF, Virtusio K, **Frye RF**, Wallace MR, Quintero LD, Sack BK, Fillingim RB. Ethnic Differences in Acute Pain and Analgesic Side Effects. Presented at the American Pain Society's 26th Annual Scientific Meeting, Washington, DC, May 2007.
126. Elewa HF, Kozak A, Rychly D, Ergul A, **Frye RF**, Fagan SC. Atorvastatin reduces intracerebral hemorrhage after experimental stroke. Presented at the American Heart Association Scientific Sessions 2007, Orlando, FL, November 2007.
127. \*Dravid P, **Frye R**. Determination of Desethylamodiaquine by liquid chromatography tandem mass spectrometry: application to CYP2C8 metabolism studies in human liver microsomes. Presented at the American Association of Pharmaceutical Scientists Annual Meeting, San Diego, CA, November 2007. AAPS Journal. 2007; 9(S2). Abstract W4056. Available from: <http://www.aapsj.org/>.
128. Nolin TD, **Frye RF**, Sadr H, Le P, Himmelfarb J. The pharmacokinetics of fexofenadine but not midazolam are altered in end-stage renal disease. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Orlando, FL, April 2008 and Clin Pharmacol Ther 2008; 83 (Supp 1):S58.
129. \*Enogieru O, Pacanowski M, **Frye RF**, Zineh I. Changes in Coenzyme Q10 (CoQ10) Following High-Dose Atorvastatin Therapy. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Orlando, FL, April 2008 and Clin Pharmacol Ther 2008; 83 (Supp 1): S82.
130. \*Mohamed MF, \*Harvey SS, **Frye RF**. Effect of ginkgo biloba and valerian root extracts on mycophenolic acid glucuronide formation in human liver microsomes. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Orlando, FL, April 2008 and Clin Pharmacol Ther 2008; 83 (Supp 1): S58.

131. Hastie BA, Stavropoulos MF, **Frye RF**, Wallace MR, Quintero LD, Tomalty S, Fillingim RB. Evidence for Response Differences in Acute Post-Operative Pain and Side Effects in a Multi-Ethnic Sample. Presented at the American Pain Society's 27th Annual Scientific Meeting, Tampa, FL, May 2008.
132. Gilbertson R, Prather R, **Frye RF**, Nixon SJ. Neurocognitive Functioning in Detoxified Substance Abusers: The Role of Nicotine and HPA Axis Function. Presented at the Volterra 2008 Meeting, Alcohol and Stress: A Framework for Future Treatment Strategies, Volterra, Italy, May 2008.
133. Nixon SJ, Gilbertson R, Prather R, **Frye RF**, Ceballos N. Stress and alcohol use in alcoholics and moderate drinkers. Presented at the Volterra 2008 Meeting, Alcohol and Stress: A Framework for Future Treatment Strategies, Volterra, Italy, May 2008.
134. Kim KM, Ouyang X, **Frye RF**, Galloway CD, Johnson RJ, Henderson GN. Simultaneous Determination of Creatinine, Uric Acid and its Metabolites in Urine, Plasma and Cell Lysates Using Liquid Chromatography-Mass Spectrometry. 56th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry, Denver, CO, June 2008.
135. Woelkart K, **Frye R**, Galloway C, Marchand S, Derendorf H, Bauer R, Butterweck V. Pharmacokinetic profiling of dodeca-2E,4E,8E,10E/Z-tetraenoic acid isobutylamides in rats using liquid chromatography tandem mass spectrometry. Presented at the 7th Joint Meeting of AFERP, ASP, GA, PSE & SIF: Natural Products with Pharmaceutical, Nutraceutical, Cosmetic and Agrochemical Interest. Athens, Greece, Aug 2008.
136. Beitelshees AL, Pacanowski MA, **Frye RF**, Zineh I. Influence of UCP2 -866G>A polymorphism on coenzyme Q10 (CoQ10) concentrations. Clin Chem Lab Med 2008;46(8):A124. Poster presentation at the 4th Biologie Perspective Santorini Conference, Santorini, Greece, Sept 2008.
137. Zdrojewski I, **Frye RF**, Galloway CD, Derendorf H, Butterweck V. Assessment of the myopathy development in rats after simvastatin grapefruit juice coadministration. Presented at the American Association of Pharmaceutical Scientists Annual Meeting, Atlanta, GA, November 2008.
138. Seder D, Riker R, **Frye RF**, Poloyac SM, Bagley A, Robbins T, Libby L, Nolin TD. Effect of therapeutic hypothermia on the pharmacokinetics of fexofenadine in cardiac arrest survivors. Presented at the Society of Critical Care Medicine's 2009 Critical Care Congress, Nashville, TN, February 2009.
139. \*Potvin M, Welder G, Zineh I, Schofield R, **Frye RF**. OATP1B1 polymorphic effects on inflammatory mediators in atorvastatin-treated subjects. Presented at the 22nd Annual Research Showcase, College of Pharmacy, University of Florida, February 2009.
140. \*Mohamed MF, Butterweck V, **Frye RF**. Herb-drug interactions: Investigating the effects of herbal supplements on the glucuronidation of drugs. Presented at the 22nd Annual Research Showcase, College of Pharmacy, University of Florida, February 2009.
141. Wölkart K, **Frye R**, Derendorf H, Bauer R, Butterweck V. Absolute Bioavailability and Metabolism of Dodeca-2E,4E,8E,10E/Z-tetraenoic acid isobutylamides ("tetraene") after Intravenous and Oral Single Doses to Rats. Presented at the 21st Scientific Congress of the Austrian Pharmaceutical Society (ÖPhG), Vienna, Austria, April 2009.
142. Gilbertson R, Prather R, **Frye R**, Klingman C, Nixon SJ. HPA Axis Function in Detoxified Substance Abusers: Nicotine and Gender Effects. 32nd Annual Research Society on Alcoholism Scientific Conference, San Diego, CA, June 2009.
143. Hastie BA, Stavropoulos MF, Wallace M, **Frye R**. Genetic and ethnic influences on acute clinical pain and post-operative opioid side effects. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Atlanta, GA, March 2010.
144. \*Mohamed MF, \*Tseng T, **Frye RF**. Evaluation of inhibitory potential of herbal extracts on UGT1A1 activity in vitro. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Atlanta, GA, March 2010.

145. \*Mohamed MF, **Frye RF**. Inhibitory effects of commonly used herbal extracts on UGT1A4, 1A6, and 1A9 enzyme activities. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Dallas, TX, March 2011.
146. Li L, Han AR, Kinghorn AD, **Frye RF**, Butterweck V. Conjugation causes low bioavailability of gamma-Mangostin in rats. Presented at the American Association of Pharmaceutical Scientists Annual Meeting, Washington, DC, October 2011.
147. Hastie B, Wallace M, **Frye R**, Boezaart A, Klodell C. A model for predicting chronic post-thoracotomy pain among patients with lung cancer. Presented at the 30th Annual Scientific Meeting of the American Pain Society, April 2011 and J Pain 2011;12:P26.
148. Hastie BA, Wallace MR, **Frye RF**, Herman MA, Stavropoulos MF. Identifying risk factors for acute post-operative pain from oral surgery in an ethnically diverse sample. Presented at the 20th International Conference on Oral and Maxillofacial Surgery, October 2011. Int J Oral Maxillofac Surg 2011;40:1051.
149. Hastie BA, Wallace MR, **Frye RF**, Hou W, Boezaart AP, Klodell CT. Predicting the Vagaries and Vestiges of Pain Following Thoracotomy. Presented at the 31st Annual Scientific Meeting, American Pain Society, Honolulu, HI, May 2012 and J Pain 2012;13:P17.
150. Stanton M, Segal M, Shuster J, **Frye R**. Green Tea Extract Reduces the Bioavailability of the OATP Probe Fexofenadine. Presented at the 2012 American College of Clinical Pharmacology Annual Meeting in San Diego, CA. Clinical Pharmacology in Drug Development 2012;1: 176.
151. Mohamed MF, Segal M, Shuster J, and **Frye R**. Effect of Quercetin on Mycophenolic acid Pharmacokinetics. Presented at the 2012 American College of Clinical Pharmacology Annual Meeting in San Diego, CA. Clinical Pharmacology in Drug Development 2012;1: 183.
152. Cooper-DeHoff RM, Hou W, Baillie R, Beitelshees AL, Gong Y, Chapman AB, Gums JG, Turner ST, Boyle SH, Zhu H, Wikoff WR, Fiehn O, **Frye RF**, Kaddurah-Daouk R, Johnson JA. Pharmacometabolomics reveals a novel signature for predicting beta blocker associated impaired fasting glucose. Circulation. 2012;126:A11088.
153. Albassam AA, **Frye RF**. Inhibitory effect of six commonly used herbal extracts on CYP2C8 Enzyme activity. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, March 2013 and Clin Pharmacol Ther 2013;93(S1):S35.
154. Suzuki-Kawaguchi M, **Frye RF**, Markowitz JS. Milk thistle herb-drug interaction study: no effect on CYP3A, CYP2C9, and CYP2D6 activities in healthy participants. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, March 2013 and Clin Pharmacol Ther 2013;93(S1):S110.
155. Hastie, BA, Klodell CT, **Frye RF**, Wallace MR. Tick-Tock...Genes working round the clock: associations with sleep and acute and chronic post-thoracotomy pain. J Pain 2013;14(4):33.
156. Kawaguchi-Suzuki M, Bril F, Lomonaco R, Subbarayan S, Cusi K, **Frye RF**. Pharmacodynamic association of pioglitazone and its active metabolites with liver outcomes among patients diagnosed with nonalcoholic steatohepatitis. Clin Pharmacol Ther 2014;95(1):S47.
157. Kawaguchi-Suzuki M, Bril F, Orsak B, Ortiz-Lopez C, Lomonaco R, Cusi K, **Frye RF**. Multivariate analysis of factors that influence improvement in nonalcoholic fatty liver disease (NAFLD) after pioglitazone treatment. Presented at the American College of Clinical Pharmacy 2014 Annual Meeting, Austin, TX, October 2014 and Pharmacotherapy 2014;34:e202.
158. Hastie BA, Wallace MR, **Frye RF**, Hou W, Boezaart AP, Wong F, Maurer MA, Gilson AM, Klodell CT. Does Pain Sensitivity Determine Trajectory? Examining the Relationships between Baseline Quantitative Sensory Testing with Acute and Persistent Post-Thoracotomy Pain. 15<sup>th</sup> World Congress on Pain, Buenos Aires, Argentina. International Association for the Study of Pain Press. 2014.

159. Hastie BA, Wallace MR, **Frye RF**, Boezaart AP, Hou W, Wallet SM, Jacobsen P, Maurer MM, Gilson AM, Klodell CT. Riding the Rollercoaster of Post-Thoracotomy Pain: Exploring Influences in the Transition to Chronic Pain. 15th World Congress on Pain, Buenos Aires, Argentina. International Association for the Study of Pain Press. 2014.
160. Bril F, Kawaguchi-Suzuki M, **Frye R**, Portillo-Sanchez P, Maximos M, Lai S, Hardies J, Tio F, Cusi K. Role of Genetic Polymorphisms in the Development of Nonalcoholic Fatty Liver Disease (NAFLD) and Steatohepatitis (NASH). Presented at the American Association for The Study of Liver Diseases Annual Meeting, Boston, MA, November 2014 and *Hepatology* 2014;60(4 suppl): 585A.
161. \*Kawaguchi-Suzuki M, Bril F, Cusi K, Langaee T, Gong Y, **Frye R**. Role of Genetic Polymorphisms on the Improvement of Liver Histology after Pioglitazone Treatment in Patients with Nonalcoholic Fatty Liver Disease (NAFLD). Presented at the American Association for The Study of Liver Diseases Annual Meeting, Boston, MA, November 2014 and *Hepatology* 2014;60(4 suppl): 591A.
162. \*MH Shahin, DM Rotroff, Y Gong, T Langaee, CW McDonough, AL Beitelshes, TJ Garrett, AB Chapman, JG Gums, ST Turner, A Motsinger-Reif, RF Frye, SE Scherer, W Sadee, O Fiehn, RM Cooper-DeHoff, R Kaddurah-Daouk, JA Johnson. Integrating Metabolomics and Genomics Reveals Novel Biomarkers of Hydrochlorothiazide Response in Pharmacogenomic Evaluation of Antihypertensive Responses (Pear) Study. *Clinical Pharmacology & Therapeutics* 2015, 97: S11.
163. \*MH Shahin, DM Rotroff, Y Gong, T Langaee, CW McDonough, AL Beitelshes, TJ Garrett, AB Chapman, JG Gums, ST Turner, A Motsinger-Reif, RF Frye, SE Scherer, W Sadee, O Fiehn, RM Cooper-DeHoff, R Kaddurah-Daouk, JA Johnson. Integrating Metabolomics and Genomics Reveals Novel Biomarkers of Hydrochlorothiazide Response in Pharmacogenomic Evaluation of Antihypertensive Responses (Pear) Study. *Clinical Pharmacology & Therapeutics* 2015, 97: S103.
164. Hastie BA, Wallace MR, **Frye RF**, Boezaart AP, Hou W, Wallet SM, Jacobsen P, Maurer MM, Gilson AM, Klodell CT. Can Thoracotomy Patients be "Immune" to Developing Chronic Pain? Examination of the Role of Immune and Inflammatory Markers in the Post-Surgical Trajectory. American Pain Society Annual Scientific Meeting, May 2015.
165. MH Shahin , AC Sa , A Webb , Y Gong , T Langaee , CW McDonough , AL Beitelshes , AB Chapman , JG Gums , ST Turner , RF Frye , SE Scherer, W Sadee, RM Cooper-DeHoff, JA Johnson. Identifying a Novel Hypertension Genetic Signature Influencing the Blood Pressure Response to Hydrochlorothiazide Treated Patients. Program/Abstract #674. Presented at the 65th Annual Meeting of The American Society of Human Genetics, October 7th, 2015 in Baltimore, MD.
166. \*de Oliveira FA, Shahin MH, Gong Y, McDonough CW, Beitelshes AL, Gums JG, Chapman AB, Boerwinkle E, Turner ST, **Frye RF**, Fiehn O, Kaddurah-Daouk R, Johnson JA, Cooper-DeHoff RM. Genomics-metabolomics Integrative Approach Reveals Novel Biomarkers in DPYS Associated with Higher Glucose Change After Treatment With Atenolol. Presented at the American Heart Association Scientific Sessions 2015, November 2015 in Orlando, FL and *Circulation* 2015; 132: A18338.
167. Voils S, Lemon S, Jordan J, Molchan S, Riley P, **Frye R**. Early Hypercoagulability in Trauma ICU Patients Detected By Calibrated Automated Thrombogram. *Critical care medicine* 11/2015; 43(12 Suppl 1):296.
168. \*Shahin MH, \*Sa AC, Webb A, Gong Y, Langaee T, McDonough CW, Riva A, Beitelshes AL, Chapman AB, Gums JG, Turner ST, Boerwinkle E, **Frye RF**, Scherer SE, Sadee W, Cooper-DeHoff RM, Johnson JA. Finding a Needle in the Haystack for Thiazide Diuretic Response Using Genomics/Transcriptomics in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. *Clin Pharmacol Ther* 2015, 99: S19.
169. \*Albassam AA, Markowitz JS, **Frye RF**. The Effect of Milk Thistle (*Silybum marianum*) and its Main Flavonolignans on CYP2C8 Enzyme Activity in Human Liver Microsomes. Presented at the American College of Clinical Pharmacology 2016 Annual Meeting, Washington, DC, September 2016 and *Clin Pharmacol Drug Dev.* 2016 Sep;5 Suppl 1:38.

170. Arwood AM, McDonough CW, Cavallari LH, Elsey AR, **Frye RF**, Gong Y, Langaee TY, Johnson JA, and Weitzel KW. Equipping Health professional students to apply pharmacogenomic data to clinical decision making in real-world scenarios: comparison of an active engagement versus didactic teaching approach. Translational Science 2017. Washington, DC. Apr 19, 2017
171. \*Mosley S, **Frye R**, Langaee T, Schmidt S.O.F., Schmidt S, Gong Y, Binkley P, Johnson JA, Cavallari LH. Determination of CYP2D6 phenotyping for metoprolol using the genotype-derived activity score. Poster presentation for ACCP Updates in Therapeutics 2018 meeting (F-42). Jacksonville, FL. February 16-18, 2018.
172. \*Thomas CD, \*Mosley SA, El Rouby N, Kim S, Lingineni K, Langaee T, Gong Y, Johnson JA, Schmidt SO, Schmidt S, **Frye RF**, Cavallari LH. Determination of CYP2D6 Phenotyping for Metoprolol using the CYP2D6 Genotype-derived Activity Score: Results from a Prospective, Clinical Trial. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, March 2019. Clin Pharmacol Ther 2019;105 (S1):S40 (LB-028).
173. Whalen K, **Frye RF**, Mobley WC, Farland MZ, and Buring SM. 2019. Disrupting the curriculum - 100% synchronous active learning across three campuses. American Journal of Pharmaceutical Education. 83 (5): 1130.
174. \*Mosley S, El Rouby N, Kim S, Lingineni K, Gong Y, Feng K, Kim H, Kinjo M, Langaee T, Schmidt S, Johnson J, **Frye R**, Binkley P, Schmidt S, Cavallari L, Zhao J, Estores D, Li Z. Randomized, Prospective, Clinical Trial Comparing Metoprolol Succinate Extended-Release (ER) Formulations. For presentation at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, March 2020 (meeting canceled due to COVID). Clin Pharmacol Ther 2020;107 (S1):S99 (PIII-080).

### RESEARCH SUPPORT

\* = active projects; TDC = total direct costs; TC = total costs

1. Influence of aging on the expression of genetic polymorphic and non-polymorphic drug metabolism. Co-Investigator. John A. Hartford Foundation, 1990-1991. TC: \$10,000.
2. Impact of computerized pharmacokinetic forecasting on practitioner competency, kinetic consultation activity and patient outcome. Co-Investigator. Demonstration Projects Program. American Society of Hospital Pharmacists Research and Education Foundation, 1990-1991. \$4,989.
3. The influence of type 1 and type 2 diabetes on the expression of genetic polymorphic drug metabolism. Co-Investigator. Diabetes Research and Education Foundation, 1990-1991. \$19,935.
4. Burroughs Wellcome Clinical Pharmacokinetics Fellowship. Fellowship, Administered by the American Society of Hospital Pharmacists Research and Education Foundation, 1991-1993. \$47,000.
5. An assessment of the fundamental relationships on which erythrokinetic modeling is based and the clinical utility of the model to guide intravenous and subcutaneous dosing of Epogen®. Co-Investigator. Amgen Clinical Grants Program, 1991-1993. \$45,000.
6. A study to determine the effect of impaired renal function on the pharmacokinetics of abecarnil. Co-Investigator. Sandoz Research Institute, 1992-1993. \$143,897.
7. Evaluation of a "cocktail strategy" to assess P450 isozyme-specific metabolic activity. Co-Principal Investigator. Upjohn Company (investigator-initiated research proposal), 1991-1992. \$5,000.
8. Characterization of hepatic P450 isozyme activity in patients with various degrees of renal function. Co-Investigator. Harris Laboratories (investigator-initiated research proposal), 1992-1994. \$24,000.
9. A study to determine the safety and pharmacokinetics of intravenous nalmefene in renally impaired patients. Co-Investigator, Ohmeda, Inc. 1993-1994. \$58,756.



10. Effect of estrogen replacement therapy on liver metabolism in young and elderly postmenopausal women. Co-Investigator, National Institutes of Health 1993-1994. \$19,440.
11. Nalmefene disposition in patients with mild, moderate, and severe hepatic dysfunction and healthy volunteers. Co-Investigator, Ohmeda, Inc. 1993-1994. \$146,042.
12. Determination of the effect of 1.25 MAC desflurane on antipyrine pharmacokinetics in the beagle dog. Co-Investigator, Ohmeda, Inc., 1993-1994. \$27,390.
13. Determination of nornalmefene concentrations after nalmefene dosing in normal subjects, subjects with moderate or severe hepatic dysfunction and subjects with renal disease. Co-Investigator. Ohmeda Pharmaceutical Products Inc. 1994. \$34,087.
14. Sex hormones and P450 activity in women with liver disease. Principal Investigator, American College of Clinical Pharmacy Research Institute. 1995-96. \$10,000.
15. Evaluation of cytochrome P450 inhibition by the chronic administration of disulfiram: effects on the disposition of chlorzoxazone and vesnarinone. Principal Investigator. Otsuka America Pharmaceuticals. 1995-97. \$88,956.
16. The effect of impaired enterohepatic recycling on the disposition of nalmefene and nalmefene glucuronide. Principal Investigator. Ohmeda Pharmaceutical Products Inc. 1996. \$41,269.
17. Evaluation of the relationship of metabolic P450 activity and circulating plasma concentrations of vesnarinone and metabolites to the occurrence of neutropenia with vesnarinone. Principal Investigator. Otsuka America Pharmaceuticals. 1996. \$31,226.
18. Drug disposition in transplant patients. Co-Investigator. (PI: Gilbert J. Burckart) NIDDK, National Institutes of Health. 1996-98.
19. Ro1-MH55756. DHEA & GABA-receptor mediated responses in aged adults. Co-Investigator. (PI: Patricia D. Kroboth) NIMH, National Institutes of Health. 1997-2001. TDC: \$685,528, TC: \$1,020,804.
20. The effect of ritonavir on the pharmacokinetics and pharmacodynamics of alprazolam. Principal Investigator. Abbott Laboratories. 1997.
21. Pharmacokinetics of valacyclovir in solid organ transplant patients. Co-Investigator. (PI: Richard Ptachcinski). GlaxoWellcome (investigator-initiated research proposal). 1997. \$35,181.
22. Evaluation of the predictive performance of EpoCalc pharmacodynamic modeling. Principal Investigator. Amgen. 1998. \$9,400.
23. Evaluation of hepatic and renal function in patients participating in OAPI 103-96-205. Principal Investigator. Otsuka America Pharmaceuticals. 1998. \$12,500.
24. In vitro metabolism/drug interaction and human clinical drug studies. FDA contract. Co-investigator (Principal investigator Robert A. Branch, M.D.) 9/97 – 11/99. \$103,500.
25. Effects of citric acid/heat and peracetic acid reprocessing on the in vitro performance of polysulfone dialyzers. Co-Investigator. (PI: Paul Palevsky, M.D.). Veterans Administration Stars and Stripes Pilot Project Fund. \$49,994.
26. Effect of peracetic acid and formaldehyde reprocessing on the in vitro performance of cellulose acetate and polysulfone dialyzers. Co-Investigator. (PI: Paul Palevsky, M.D.). Dialysis Clinics, Inc., Paul Teschan Research Fund. \$49,708.
27. Evaluation of the effect of SB 223412 on the metabolism of multiple cytochrome P450 substrates. Principal Investigator. SmithKline Beecham. 2000. \$101,568.
28. A study to assess the effect of 1555U88 on probe drugs eliminated by cytochrome P450 enzymes in healthy volunteers. Principal Investigator. GlaxoWellcome. 2000. \$39,244.

29. N01-CM97019-58. Preclinical pharmacological studies of antitumor and anti-HIV agents. Co-investigator (PI: Merrill Egorin, MD), National Cancer Institute, NIH. 12/01/00 - 12/31/02. TDC: \$890,925 TC: \$1,285,232.
30. P30 MH 52247. Interventions Research Center for the Study of Late-Life Mood Disorders (Principal Investigator Charles F. Reynolds III, MD; R.F. Frye, Co-investigator, Psychopharmacology Core). TDC (years 6 – 10; 3/2000 – 2/2005): \$5,432,131. TC: \$8,121,693.
31. R01-CA59834. Drug Metabolizing Enzymes - Risk Factors in Bladder Cancer (R01). Co-investigator (PI: Robert A. Branch), National Cancer Institute, NIH. 07/01/01 - 06/30/05. TDC: \$890,925 TC: \$1,285,232.
32. In vitro studies of the effects of St. John's wort on the metabolism of docetaxel. Co-investigator (PI: Merrill Egorin, MD). Rhone Poulenc Rhorer (RPR) Grant-in-aid. 07/01/02 – 06/30/03. TDC: \$91,187 TC: \$113,984.
33. R01-DK59519. Drug metabolism in chronic liver disease (R01). Co-investigator (PI: Robert A. Branch), National Institute of General Medical Sciences, NIH. 09/15/02 - 09/14/07. TDC: \$1,296,315, TC: \$1,934,334.
34. R01-MH63458. St. John's wort and CYP3A metabolism in Men & Women. Principal Investigator. National Institute of Mental Health, NIH. 05/01/2001 – 04/30/2005. TDC: \$650,000, TC: \$1,001,292.
35. R01-GM63215. Mechanisms of atypical drug kinetics and interactions (R01). Co-investigator (PI: Timothy S. Tracy, West Virginia University), National Institute of General Medical Sciences, NIH. 07/01/2001 - 06/30/05. TDC: \$625,000. University of Pittsburgh subcontract: TDC: \$83,612, TC: \$125,000. University of Florida subcontract TDC: \$34,483, TC: \$50,000.
36. Effect of St. John's wort on Gleevec Pharmacokinetics. Principal Investigator. Novartis Investigator Initiated Research Program. 12/2002 – 06/2004. TC: \$59,960.
37. A Double-Blind, Parallel, Randomized, Placebo-Controlled, Ascending Repeat-Dose Study to Investigate GW695634X and GW678248X Safety, Tolerability and Pharmacokinetics following Oral Administration of GW695634G to Healthy Subjects for 10 Days. Principal Investigator. GlaxoSmithKline. 10/04 – 12/05. TC: \$54,960.
38. Effect of BAY 43-9006 on CYP3A activity in patients with advance refractory cancer. Principal Investigator (consulting and analytical services). Bayer Corporation, 12/04 – 12/05. TC: \$28,056.
39. Effect of Kidney Disease on CYP3A Metabolism and P-glycoprotein Transport. Co-investigator (PI: Thomas Nolin), Satellite Healthcare, 07/05 – 06/07. TC: \$130,000.
40. A Phase I, Single-Center, Open-Label, Multiple-Probe Drug Interaction Study to Determine the Effects of GW823093 on the metabolism of CYP450 Probe Substrates in Healthy Subjects (GSK Study 102875). Principal Investigator. GlaxoSmithKline. 8/05 – 2/07. \$135,476.
41. K01-NS055094; NIH/NIDDS; (PI: Dr. Barbara Hastie). Ethnic Differences in Acute Pain and Analgesic Response. Co-Mentor. 04/06 – 03/11.
42. Effect of Therapeutic Hypothermia on Drug Metabolism and Transport in Cardiac Arrest Patients. Co-investigator (PI: Dr. Thomas Nolin), Maine Medical Center Research Institute, 08/08 – 07/09. Subcontract TC: \$5,382.
43. R01-HL079352. Uric acid and hypertension in African-Americans. Co-investigator (PIs: Dr. Mark Segal and Rick Johnson). NIH/NHLBI, 08/08 – 04/09. TC: \$671,312. Subaward TC: \$11,720.
44. R21-DE019267. Sex Differences in Acute Pain and Analgesic Responses: Psychosocial and Genetic Influences. Co-investigator (PI: Dr. Barbara Hastie). 07/09 – 06/12. TC: \$401,620. Subaward TC: \$82,885.
45. RC2-GM092729. Metabolomics Network for Drug Response Phenotype. University of Florida Consortium PI (PI: Rima Kaddurah-Daouk). 09/09 – 09/12. TC: \$4,507,931. Subaward TC: \$310,479.
46. R21-AT005083. Herb-Drug Glucuronidation Interactions. Principal Investigator. National Center for Complementary and Alternative Medicine/NIH. 9/30/2010 – 9/29/2013. TDC: \$400,000, TC: \$574,376.
47. U01 GM074492. Pharmacogenomic Evaluation of Antihypertensive Response (PEAR). Co-investigator (PI: JA Johnson). 8/1/2010 – 07/31/2015. TDC: \$9,183,953, TC: \$10,621,007.

48. American Cancer Society. Mechanism Predicting Pain Trajectory among Cancer Patients. Co-investigator (PI: Dr. Barbara Hastie). 1/1/2011 – 12/31/2014. TDC: \$400,000, TC: \$480,000.
49. U01 HG007269. Genomic medicine implementation: The Personalized Medicine Program. Co-investigator (PI: JA Johnson). 04/2013 – 03/2017. TDC: \$2,504,467, TC: \$3,749,997.
50. UF CTSI Clinical Pilot Award. The Effect of Low Furanocoumarin Grapefruit Hybrid Juice Consumption on Midazolam Pharmacokinetics. (PI: Cooper-DeHoff). 11/2013 – 11/2014. \$22,160.
51. UF CTSI and Southeast Center for Integrated Metabolomics (SECIM) Pilot Award. A targeted pharmacometabolomic investigation of the acylcarnitine pathway and incident impaired fasting glucose. (PI: Cooper-DeHoff). 5/2014 – 4/2015. \$20,240.
52. Isagenix™ International LLC (PI: Markowitz). Relative Bioavailability of Two Different Milk Thistle Formulations: A Single Dose Randomized Crossover Pharmacokinetic Study. 02/2016 – 2/2018 \$91,663.
53. U01-FD005235, Food and Drug Administration. Pharmacokinetic and Pharmacodynamic (PK-PD) Studies of Cardiovascular Drugs. (MPI: Larisa Cavallari, contact, and Julie Johnson). 09/2014 – 8/2019. TDC: \$1,555,246, TC: \$2,332,870.
54. Medical Marijuana Consortium (PI: Markowitz). An Assessment of the Drug Interaction Potential Between Oral Cannabidiol (Epidiolex®) and the CES1 Substrate Methylphenidate in Healthy Volunteers. 7/1/2020-6/30/2021. \$75,000. \*

### PRESENTATIONS

The Role of Drug Metabolizing Enzymes in Chemical Carcinogenesis. University of Pittsburgh, School of Pharmacy, February 1992.

Pharmacokinetics and Pharmacodynamics of Torsemide, a potent loop diuretic. University of Pittsburgh, School of Pharmacy, April 1993.

Vancomycin Therapeutic Drug Monitoring: Dosing for a target level at a target time and fitting serum levels. Satellite Workshop on Bayesian Individualization of Drug Dosage Regimens, Nonparametric EM Population Pharmacokinetic Modeling, Modeling Drug Diffusion into Endocardial Vegetations, and Bacterial Killing Curves, Philadelphia, PA, May 1993.

Erythrokinetic Modeling for the chronic hemodialysis patient. University of Pittsburgh, School of Pharmacy, January 1994. University of Arizona, School of Pharmacy, February 1994. Medical College of Virginia, March 1994.

Characterization of *In Vivo* Drug Metabolizing Enzyme Activities: Validation of Chlorzoxazone as a Probe of CYP2E1 and a Cocktail to Assess Multiple Enzymes. University of Pittsburgh, June 14, 1995.

Use of a cocktail strategy to assess drug and disease state effects on *in vivo* CYP450 activity. Abbott Laboratories, December 7, 1995.

Methods to assess CYP activity in patients with renal disease. American Society of Clinical Pharmacology Renal Section Symposium: Research Methods for Renal Pharmacology. March 21, 1996.

CYP activity in patients with varying degrees of renal function. Renal Grand Rounds, University of Pittsburgh. March 28, 1996.

The Cytochrome P<sub>450</sub> enzyme system: Alphabet Soup? Brigham & Women's Hospital, Department of Pharmacy. May 9, 1996.

Methods to assess *in vivo* cytochrome P<sub>450</sub> activity. Brigham & Women's Hospital, Department of Obstetrics and Gynecology. May 9, 1996.

Mono-acetyldapsone disposition is altered in the presence of disulfiram. School of Pharmacy Seminar Series, University of Pittsburgh, February 20, 1997.

Application of the "Pittsburgh Cocktail" approach to drug interaction studies. Presentation to visiting FDA scientific reviewers, Center for Clinical Pharmacology, June 1997.

Assessment of *in vivo* CYP enzyme activity in humans. Center for Clinical Pharmacology, August 1997.

Drug interactions with the protease inhibitor ritonavir. Center for Clinical Pharmacology Seminar Series, November 1997.

A generalized approach for determining the potential for drug interactions *in vivo*. Presented at the 17<sup>th</sup> Annual Rozman Symposium on Drug Metabolism, Delaware Valley Drug Metabolism Discussion Group, Philadelphia, PA, May 1998.

Clinical significance of cytochrome P<sub>450</sub> (CYP) enzymes. Housestaff Patient Management Conference, Montefiore University Hospital, September 1998.

Flurbiprofen and the Pittsburgh Cocktail: Should it stay or should it go now? Center for Clinical Pharmacology Seminar Series, December 1998.

The Pittsburgh Cocktail Approach: A generalized approach for assessing drug and disease state effects on *in vivo* CYP activity. West Virginia School of Pharmacy, Morgantown, WV, March 1999.

Effect of Congestive Heart Failure on drug metabolism: Relevance to cardiovascular pharmacotherapy. Cardiovascular Institute, University of Pittsburgh, April 1999.

A generalized *in vivo* approach for determining the potential for drug-drug interaction. Presented at the Barnett International Conference: Predicting, Managing, and Understanding Drug-Drug Interactions. September 1999.

A generalized *in vivo* approach for assessing drug and disease state effects on cytochrome P<sub>450</sub> (CYP) enzymes. Senior Vice Chancellor's Research Seminar Series. July 2000.

Strategies for *In Vivo* Assessment of Drug Interaction Potential: Selection and Application of Probe Substrates. Presented at the 2<sup>nd</sup> Annual Barnett International Conference: Predicting, Managing, and Understanding Drug-Drug Interactions. October 2000.

Interindividual Variability in Drug Response: Pharmacokinetics and Genetics. Presented at the Conference on Chronic Disorders: "Methodological Issues in Studies of Adherence" workshop sponsored by the University of Pittsburgh School of Nursing Center for Research in Chronic Disorders, October 2000.

Drugs and Genes. University of Pittsburgh Discovery Weekend, School of Pharmacy, University of Pittsburgh. October 2000.

Interindividual Variability in Response: Pharmacogenetic Determinants. University of Pittsburgh, School of Pharmacy. January 2001.

Pharmacogenetics of Drug Metabolism. Molecular Therapeutics / Drug Discovery Seminar Series, University of Pittsburgh Cancer Institute. May 2001.

Pharmacogenomics. GEAR-UP program, School of Pharmacy, University of Pittsburgh. February 2002.

Characterization of Genetic and Non-Genetic Factors that affect Cytochrome P<sub>450</sub>-Mediated Metabolism *In Vivo*. College of Pharmacy, University of Florida, October 2002.

New and Improved Methodologies for Measuring Drugs and Metabolites in Biological Fluids. ACCP Spring Practice and Research Forum, April 2003.

Advances and Updates in Chromatography – Workshop. ACCP Spring Practice and Research Forum, April 2003.

Application of Probe Drugs to Estimate *In Vivo* Activity of Drug Metabolizing Enzymes. 2003 Workshop, Advanced Methods of PK/PD Systems Analysis, sponsored by the Biomedical Simulations Resource, University of Southern California, June 2003.

Selection and Application of Probe Substrates for Assessing Potential Drug-Drug Interactions *In Vivo*. 6th International Conference on Drug-Drug Interactions, sponsored by the Institute for Scientific Exchange, Inc. June 2003.

Probing the World of Cytochrome P<sub>450</sub> Enzymes. Center for Food-Drug Interaction Research and Education and Department of Pharmaceutics, University of Florida, February 2004.

Variability in drug response: Herbs, SNPs, and CYPs. College of Pharmacy Faculty Research Forum, University of Florida, May 2004.

Herb-Drug Interactions. 55<sup>th</sup> Annual Wisconsin Pharmacy Institute: An Update on Herbal and Nutritional Therapies. University of Wisconsin, Madison, WI, November 2004.

In vivo evaluation of CYP activity: Clinical Implications of genetic polymorphism. AAPS short course: An update on Cytochrome P<sub>450</sub> (CYP<sub>450</sub>). AAPS Annual Meeting, Baltimore, MD, November 2004.

Effect of CYP<sub>2C8</sub> Pharmacogenetics and Drug Interactions on Rosiglitazone Pharmacokinetics. Department of Pharmacy Practice, College of Pharmacy, University of Florida, April 2005.

Effect of Chronic Kidney Disease on the Drug Metabolism Phenotype. Department of Pharmacy Practice, College of Pharmacy, University of Florida, March 2006.

Effect of Aging on Cytochrome P<sub>450</sub>-mediated Metabolism. Institute on Aging Research Seminar Series, College of Medicine, University of Florida, March 2006.

Clinical Pharmaceutical Sciences at the University of Florida. Clinical Scientist Task Force Open Hearing, American Association of Colleges of Pharmacy Annual Meeting, San Diego, July 2006.

Effect of disease and inflammation on cytochrome P<sub>450</sub> mediated metabolism in man. Drug Metabolizing Enzymes and Disease Pathogenesis Symposium, AAPS Annual Meeting, San Antonio, TX, November 2006.

Pharmacogenetics and Drug Abuse Research. Interdisciplinary Drug Abuse Research Group Seminar Series, University of Florida, February 2007.

Effect of genotypic variation on CYP<sub>2C8</sub> phenotype. DMET Forum, Affymetrix, Santa Clara, CA, March 2007.

Pharmacogenetic and environmental factors that alter human drug metabolism. Invited Distinguished Alumni Speaker, Oglethorpe Symposium, Oglethorpe University, Atlanta, GA, April 2007.

Variability in drug metabolism: Interactions, SNPs, and CYPs. Keynote Speaker, School of Pharmacy Research Day, University of Iowa, April 2007.

Role of Pharmacogenetics in Primary Care. The New Drug Update, Continuing Education Symposium, Medical University of South Carolina, Charleston, SC, May 2007. (ACPE credit 1 hour)

Mechanisms and Assessment of Drug Interactions Involving Metabolic Enzymes. ACCP Annual Meeting, Curricular Track 4 – Approach to Complex Drug Interactions: Clinical and Research Applications. Denver, CO, October 2007.

NIH peer Review: Criteria for Scoring and Review. ACCP Focused Investigator Training (F.I.T.) program, Salt Lake City, UT, July 2008. (ACPE credit 1 hour)

Genetic and Environmental Factors that alter Drug Response. University of Florida Pre-Pharmacy Society, October 2008.

NIH peer Review: Criteria for Scoring and Review. ACCP Focused Investigator Training (F.I.T.) program, Salt Lake City, UT, July 2009. (ACPE credit 1 hour)

K vs. R: What's right for me? ACCP Focused Investigator Training (F.I.T.) program, Salt Lake City, UT, July 2009. (ACPE credit 1 hour)

Genetic and Environmental Determinants of Drug Response. University of Florida Pre-Pharmacy Society, January 2010.

Application of Hydrophilic Interaction Liquid Chromatography Mass Spectrometry to Support Drug Metabolism Studies. LC-MS/MS in Clinical Pharmacology, 2010 PITTCO, Orlando FL, March 2010.

Genetic and Non-Genetic Determinants of Cytochrome P<sub>450</sub>-Mediated Drug Metabolism. School of Pharmacy, University of Southern California, March 2010.

NIH peer Review: Criteria for Scoring and Review. ACCP Focused Investigator Training (F.I.T.) program, Tucson, AZ, June 2010. (ACPE credit 1 hour)

Intro to NIH for New Investigators: Types of Awards Available and How to Select the Right One. ACCP Focused Investigator Training (F.I.T.) program, Tucson, AZ, June 2010. (ACPE credit 1 hour)

Incorporating Pharmacogenomics into the Curriculum: The University of Florida Experience. American Association of Colleges of Pharmacy Annual Meeting, Pharmacogenomics Special Interest Group, Seattle, WA, July 2010.

Effect of Liver Disease on Drug Metabolism and Transport. Drug Dosing in Patients with Hepatic Impairment Symposium, 2011 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, March 2011.

Intro to NIH for New Investigators: Types of Awards Available and How to Select the Right One. ACCP Focused Investigator Training (F.I.T.) program, Tucson, AZ, June 2011. (ACPE credit 1 hour)

NIH peer Review: Criteria for Scoring and Review. ACCP Focused Investigator Training (F.I.T.) program, Tucson, AZ, June 2011. (ACPE credit 1 hour)

Pharmacometabolomics: Identifying Novel Biomarkers of Drug Response. Department of Pharmacotherapy and Translational Research, College of Pharmacy, August 2011.

Metabolomic Signatures of Antihypertensive Drug Response. Plenary Session: Metabolomic Applications for Assessing Drug Response and Toxicity. 2011 Annual Meeting of the International Society for the Study of Xenobiotics (ISSX), Atlanta, GA, October 2011.

Transport-mediated dietary supplement-drug interactions. Dietary Supplement – Drug Interactions Workshop, National Center for Complementary and Alternative Medicine, NIH, Bethesda, MD, March 2012.

Transporter-based drug interactions, Department of Pharmaceutics, UF College of Pharmacy, March 2012.

Pharmacogenetics Overview: Genetic Variants in Drug Metabolic Pathways and Targets, Basic and Clinical Science Symposium: The Expanding Role of Pharmacogenomics in Nephrology, American Society of Nephrology Annual Meeting, San Diego, CA, November 2012.

Criteria for Inclusion of Drugs in a Testing Matrix for Predicting Interactions. Dietary Supplement – Drug Interaction Expert Panel Meeting, National Center for Complementary and Alternative Medicine, NIH, Bethesda, MD, April 2013.

Clinical and Translational Research Programs and Progress, Curricular Track III: Pharmacy-Based Clinical and Translational Science: Opportunities for Innovative Practice and Research—Models of Clinical and Translational Research. ACCP 2013 Annual Meeting, Albuquerque, NM, October 2013.

NIH 101: Appreciate the mission, Identify the appropriate program, and finding funding. ACCP Focused Investigator Training (F.I.T.) program, Athens, GA, July 2014 (ACPE credit 1 hour).

Teaching and Practice of Clinical Pharmacogenetics. Symposium for the PK/PD/Pgx PRN Focus Session—Debates in the Teaching and Practice of Clinical Pharmacokinetics & Pharmacogenetics. ACCP 2014 Annual Meeting, Austin, TX, October 2014 (ACPE credit 1 hour).

Evaluation of Herb-Drug Interactions mediated through drug metabolism and transport. Department of Pharmaceutics, South Dakota State University College of Pharmacy, November 2014.

Pharmacogenomic biomarkers and personalized medicine: focus on cytochrome P<sub>450</sub> enzymes. Keynote speaker for Annual Pharmacy Research Presentations and Keo Glidde Smith Fall Pharmacy Convocation, South Dakota State University College of Pharmacy, November 2014.

Clinical and Pre-clinical evaluation of herb-drug interactions mediated through drug metabolism and transport. University of Florida Complementary and Alternative Medicine (UF-CAM) Interest Group, December 2014.

Potential for natural product-drug interactions mediated through conjugative drug metabolism. 15th Annual Oxford International Conference on the Science of Botanicals, National Center For Natural Products Research, and School of Pharmacy, University of Mississippi, April 2015.

Personalized Medicine. College of Pharmacy, University of Florida, October 2015.

Training Opportunities in Clinical Pharmaceutical Sciences. Florida A&M University College of Pharmacy & Pharmaceutical Sciences, PharmD Student Forum, October 2015.

Teaching Strategies for Clinical Pharmacogenomics. University of Florida Precision Medicine Conference. Lake Nona, FL. March 12, 2016.

Pharmacogenetics of Drug Metabolism (five lectures). Pre-conference lectures. University of Florida Precision Medicine Conference. Lake Nona, FL. March 2016, February 2017, February 2018.

Investigating Sources of Variability in Drug Response. University of Pittsburgh School of Pharmacy Graduate Program Retreat, Seven Springs, PA, June 20, 2019.

Role for Cannabidiol in Modulating Hepatic Steatosis? UF College of Medicine, Division of Endocrinology, Diabetes, & Metabolism Research Conference, June 26, 2019.

Disease-Drug Interaction: Effect of NASH on Hepatic Uptake Transporters. UF College of Medicine, Division of Endocrinology, Diabetes, & Metabolism Research Conference, November 6, 2019.